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INTRODUCTION 
The determination of the growth status of an individual plays a vital role in deciding the 
orthodontic treatment plan. The growth modification therapy carried out particularly during peak 
pubertal growth spurt provides a successful treatment outcome within a reduced period of time.38 
It is believed that girls have an earlier onset of puberty when compared to boys. The accelerating 
phase of growth may last for 2 years on average so this aspect should be taken into consideration 
while making clinical decisions for any growth modification procedures.43 
Each and every individuals matures differently according to his or her own biological clock. So 
there are different methods that had been reported by different authors to determine the skeletal 
maturity of an individual such as height, weight, chronological age, sexual maturation, frontal 
sinus, biological age, hand wrist radiograph, cervical vertebrae, dental eruption, dental 
calcification stages and recently biomarkers.44 
Greulich and Pyle (1959) and Fishman (1982) determined skeletal maturation using the hand 
wrist radiograph. It is a popular and reliable indicator for determining the skeletal maturation but 
it requires an additional radiograph and an unwanted radiation exposure to the patient. 
Lamparski (1972) 19 assessed the skeletal maturation based on the morphology of cervical 
vertebrae. Hassel B and Farman A (1995) 12 used the lateral cephalogram and studied C2, C3 and 
C4 to develop a reliable method for identifying adolescent growth potential. One advantage of 
CVM method is that a lateral cephalometric radiograph is routinely required for orthodontic 
diagnosis and treatment planning, so no additional radiograph is required.34 
Gandini et al 28 and Flores-Mir et al 6 compared hand wrist bone radiograph with cervical 
vertebral radiograph for measuring skeletal maturation and found that vertebral analysis on a 
lateral cephalogram is as valid as the hand wrist bone analysis. The CVM method is comprised 
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of six maturational stages (CS1-CS6) with the peak skeletal maturation occurring between CS3 
and CS4. The detection of CS2 indicates that the growth spurt is approaching and occurs one 
year after CS2.52 
           Biochemical markers are also used for determining the skeletal maturity status and they 
include systemic growth factors like growth hormone (GH), insulin like growth factor-1 (IGF1), 
thyroid hormones, glucocorticoids, estrogen and testosterone and local factors which are 
involved in growth regulation are Ihh, PTHrP, FGF, BMPs, VEGF, Wnt5a, Wnt5b, Sox 5, 6 & 9, 
Runx2, HIF-1 alpha, RANKL, OPG, CSF, c-FOS and IGF1. These biochemical markers of 
skeletal maturity were initially found to be detected in serum. Recently the presence of these 
growth factors in saliva has been identified.25 
           Salmon and Daughaday discovered IGF1 in 1957 as a mediator of growth hormone (GH) 
function, which was termed as sulphation factor. IGF1 is a circulating GH factor so its level in 
serum can be used to identify sexual maturity. Its level does not fluctuate throughout the day so 
precise assessment of IGF1 is a useful diagnostic tool for determining skeletal maturity.33,43   
Masoud et al and Ishaq et al assessed skeletal maturity by using blood spot IGF1 level.25,26  
Various methods that are used for analyzing IGF-1 are radioimmunoassay (RIA), enzyme linked 
immunosorbent assay (ELISA) and chemiluminescence immunoassay (CLIA).33,38,42 There were 
a significant correlation between cervical skeletal maturity and the biochemical marker from 
prepuberty to late pubertal stages. 
            Costigan et al 7 demonstrated the presence of free IGF1 in human saliva. Antonelli et al 1 
investigated the presence of IGF1 in saliva and compared it with plasma free IGF1. Salivary 
IGF1 levels are extremely low i.e less than 1% of serum levels and salivary IGF1 level reflects 
its plasma level.25 IGF1 in women was found to be significantly higher than in men.8          
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Nayak et al 42  had studied the relationship between salivary IGF1 and cervical maturation stages 
for determining the skeletal maturity. They found that highest levels were at the highest velocity 
stage and thereafter a gradual drop in salivary IGF1 level was detected. Thus salivary IGF1 level 
is a reliable method for predicting  pubertal growth spurt and  it is also a noninvasive method. 
           Rabie et al 31 studied the expression of growth factors regulating mandibular condylar 
growth. It was found that inactivation of vascular endothelial growth factor (VEGF) suppressed 
neovascularization and endochondral bone formation in the epiphyseal growth plate of rats. The 
reintroduction of VEGF caused capillary invasion and bone growth. Also highest levels of VEGF 
expression coexisted with the highest level of bone formation. VEGF is able to promote 
ossification by either inducing neovascularization or by directly affecting the bone cells.57  
          Huang et al 14 found that  VEGF not only plays a vital role in angiogenesis but also induces 
bone remodeling. Shum et al 21 assessed the amount of VEGF expression and bone formation in 
posterior glenoid fossa during stepwise mandibular advancement. There were greatest increase in 
VEGF expression preceding new bone formation. Therefore, they concluded that an increase of 
VEGF is temporarily related to the amount of new bone formation. Brozovic et al 45 and 
Taichman et al 48 studied the presence of VEGF in saliva using enzyme linked immunoassay 
(ELISA) method. 
            Routinely radiographs were used for determining skeletal maturity but recently many 
studies were done on biomarkers to determine skeletal maturity as they avoid radiation exposure. 
Many researches had been done to evaluate the Insulin like growth factor-1(IGF-1) and Alkaline 
phosphatase in serum and gingival crevicular fluid. But no study till date has evaluated the level 
of vascular endothelial growth factor in determining skeletal maturity. 
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            This present study is intended to find out the activity levels of insulin like growth     
factor-1 (IGF-1) and vascular endothelial growth factor (VEGF) in saliva and to correlate it with 
the various stages of cervical vertebral maturation indicator to confirm whether any definitive 
change is occurring during the peak pubertal growth period.
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AIM AND OBJECTIVES OF THE STUDY 
AIM: 
          The aim of this study is to quantitatively evaluate the insulin like growth factor 1 and 
vascular endothelial growth factor level during various stages of cervical vertebral maturation 
and to find its correlation with skeletal maturity. 
OBJECTIVE: 
1) To evaluate the levels of insulin like growth factor - 1 during various stages of 
cervical vertebral maturation. 
2) To evaluate the levels of vascular endothelial growth factor during various stages of 
cervical vertebral maturation. 
3) To find out whether there is any gender differences in insulin like growth factor 
levels and vascular endothelial growth factor levels. 
Also to find whether these two biomarkers can be used to determine the skeletal maturity of an 
individual by correlating its value with cervical vertebral maturation stage
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REVIEW OF LITERATURE 
Colm Costigan et al (1988) 7 studied the presence of insulin like growth factor 1 (IGF-1) in 
human saliva and correlated with plasma GH levels. Mixed saliva samples were taken from 14 
normal subjects and after centrifugation, the clear supernatant was collected and used for the 
assay. All the samples were assayed by RIA (Radioimmunoassay) method. In this study salivary 
IGF1 concentration did not change with increasing salivary flow rates above normal or with 
storage of samples at room temperature for up to 24h before freezing. The mean IGF1 
concentration in mixed saliva was 2.3 ± 0.3 ng/ml and their mean plasma IGF1 level was 315 ± 
27 ng/ml. The study concluded that saliva contains free IGF1 and IGF1 level reflects the GH 
status of the donor. 
Maria T.O’ Reilly et al (1988) 22 assessed the relationship of cervical vertebral maturation and 
mandibular growth changes in annual lateral cephalometric radiographs. The samples were 
obtained from Bolton-Broadbent growth study. It consisted of yearly lateral cephalometric 
radiographs of 13 Caucasian females with ages ranging down from 9 to 15 years. The 
measurement of mandibular length, corpus length and ramus height were compared with the 
stages of cervical vertebral maturation. The result was found to be significant increase in 
mandibular growth changes associated with specific maturation stages of cervical vertebrae. 
Ryan J et al (1992) 36 studied the insulin like growth factor 1 (IGF-1) concentrations in human 
saliva from birth through puberty. Mixed saliva samples were collected from 327 normal 
subjects, age ranging from birth to adolescence. The samples were analyzed by RIA 
(Radioimmunoassay) method. IGF1 level was found to be low during early childhood, rising 
with age, peaking in puberty and falling again in late adolescence. Salivary IGF1 concentrations 
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were 100 to 200 folds less than plasma IGF1 levels and also there is no difference between male 
and female samples apart from pubertal influences. 
   S. Halimi et al (1994) 13 studied the concentration of insulin like growth factor-1 (IGF-1) in 
saliva of acromegalic patients and compared with the serum IGF-1 level and growth hormone. 
The study included 13 healthy adult individuals and 17 acromegalics . IGF-1 was determined in 
extracted saliva and serum using RIA (Radio immuno assay) method. When compared with 
healthy subjects, acromegalics had significantly higher level of IGF-1 concentrations and 
somatotropin levels. However salivary IGF-1 concentrations of active acromegaly patients were 
within the normal range. Serum IGF-1 and somatotropin concentration were found to follow 
more closely towards disease activity. These results suggest that IGF-1 levels in serum and saliva 
are somatotropin dependent. Also measurement of IGF-1 in saliva is less reliable than the 
determination of  IGF-1 and somatotropin in serum. 
Johannes Pammer et al (1998) 16 investigated the expression of vascular endothelial growth 
factor (VEGF) in normal and pathological salivary gland tissues. In situ hybridization revealed 
distinct labelling of VEGF mRNA in normal and tumoural salivary gland tissues. Saliva samples 
collected from 24 healthy volunteers revealed high concentrations of VEGF ranging from 0.10 to 
2.50ng/ml were detected. Thus the author concluded that VEGF is constitutively expressed in 
normal human salivary glands and in saliva of healthy individuals. The presence of considerable 
quantities of VEGF in normal human saliva suggests its important role in the maintenance of 
homeostasis and accelerates wound healing by neoangiogenesis within the oral cavity. 
Taichman NS et al (1998) 48 studied the presence of vascular endothelial growth factor (VEGF), 
a potent, multifunctional, angiogenic cytokine in normal human saliva. VEGF was measured by 
ELISA (enzyme linked immunosorbent assay) in whole saliva (median concentration, 460 
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pg/ml). They found that VEGF seems to be synthesized endogenously by salivary glands because 
both VEGF mRNA and protein were localized to serious acinar cells and ductal epithelial cells 
within the parotid, submandibular and minor salivary glands. All findings point the existence of a 
“Salivary VEGF System”. 
Martine M. L. Deckers et al (2000) 24 investigated the expression of vascular endothelial 
growth factor (VEGF) and their receptors during osteoblast differentiation using the mouse 
preosteoblast like cell line KS483 during early differentiation of osteoblast. KS483 cells express 
low levels of VEGF mRNA, whereas during mineralization, KS483 cell express high level of 
VEGF mRNA. VEGF production during osteoblast differentiation was stimulated by insulin like 
growth factor 1 which enhances osteoblast differentiation and was inhibited by PTH related 
peptide which inhibits osteoblast differentiation. Thus the expression pattern of VEGF and their 
receptors play an important role in bone formation by stimulating osteoblast differentiation. 
Shoshana Yakar et al (2000) 40 reviewed about the growth hormone/insulin like growth factor-1 
system and its implications on organ growth and development. Growth hormone (GH) and 
insulin like growth factors (IGFs) are essential for normal growth and development during 
embryonic and postnatal stages. GH has little effect prenatally whereas the IGFs are essential 
during these stages. GH-IGF1 axis is important for pubertal growth. So in order to determine 
whether postnatal growth and development are dependent on circulating or locally processed 
IGF-1, the IGF-gene in the liver were deleted in mice using cre/LoxP system used for tissue 
specific gene deletion. It was found that these animals demonstrated 75-80% reduction in 
circulating IGF-1 and four fold increase in circulating GH. Despite the marked reduction in 
circulating IGF-1 growth and development was normal. Thus the liver production of IGF-1 is not 
essential, whereas autocrine/paracrine IGF-1 production is sufficient for normal growth and 
development. 
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Rabie et al (2002) 30 studied the VEGF expression and bone formation in the glenoid fossa 
during natural growth and compared with that during forward mandibular positioning. The 
samples consisted of 150 female Sprague – Dawley rats, 35 day old were randomly divided into 
10 experimental and 10 control groups. The rats were then killed at different times. Sections 
were cut and stained with anti – VEGF antibodies to evaluate VEGF expression. The results 
showed that there were significant increase of VEGF and new bone formation in the 
experimental groups when compared with the controls. The highest amount of VEGF expression 
was found before the highest amount of bone formation has reached. 
Rabie et al (2002) 31 studied the factors regulating condylar growth that has not been identified 
before such as Sox9 transcription factor and vascular endothelial growth factor (VEGF). Samples 
of 115 Sprague – Dawley rats, 35 day old were used in this study. They were killed at 38, 42, 49, 
59 and 65 days of age. Tissue sections were made and the expressions of these factors were 
identified on protein level by using immuno staining. It was found that the Condylar growth 
involves a sequence of stages, defined by molecules that are intrinsically synthesized by cells in 
the condyles and also the expression of VEGF by chondrocytes reaches its maximum level of 
preceding bone formation. 
Rabie et al (2002) 32 investigated the expression of VEGF (Vascular Endothelial Growth Factor) 
and new bone formation in the condyle during forward mandibular positioning. One hundred and 
fifty samples of 35 day old female Sprague-Dawley rats were taken in this study. The rats were 
divided into 10 groups. Each group consisted of 10 rats in which five were fitted with bite 
jumping appliances and remaining five untreated. One group was sacrificed on each of 
experimental day 3, 7, 14, 21, 30, 33, 37, 44, 51 and 60 respectively. Sagittal sections were cut 
and stained with VEGF antibodies. Each section was quantitatively analyzed using computer 
software. The result was found to have a significant increase in both vascularization and 
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mandibular bone growth upon forward mandibular positioning. Highest amount of both the 
VEGF and mandibular bone growth was seen in the posterior region of the condyle.  
Shoshana Yakar et al (2002) 41 studied whether the circulating level of IGF-1 directly has a role 
in regulating bone growth and density. IGF are bound to a family of six structural IGF binding 
proteins (IGFBP1 through IGFBP6). Majority of IGF (70 – 80%) exists in a 150-kDa complex 
comprising of one IGF molecule, IGFBP-3 and the acid labile subunit (ALS) in serum. Liver 
IGF-1 deficient (LID) mice and ALS knockout (ALSKO) mice had relatively normal growth. 
Whereas double gene disrupted mice generated by crossing LID +ALSKO mice exhibited a 
reduction in linear growth and serum IGF-1 level. The proximal growth plates of tibia, bone 
mineral density, periosteal circumference and cortical thickness were reduced in these mice. 
Treatment with IGF-1 for 4 weeks restored the normal growth and development. Thus the 
circulating IGF-1 have a role in directly regulates normal bone growth and density. 
Suzana Brozovic et al (2002) 45 investigated the association of vascular endothelial growth 
factor (VEGF) with various stages of recurrent aphthous ulceration (RAU). Samples of saliva 
were collected from 27 healthy controls age and sex matched and 30 patients with minor and 
major RAU grouped into three stages. VEGF levels were determined by enzyme linked immuno 
assay using Human VEGF ELISA Kit. The results were expressed in pg of VEGF/ml. VEGF 
levels decreased in patients with RAU when compared to healthy controls.  
Tiziano Baccetti et al (2002) 51 had done a study to provide an improved version of cervical 
vertebral maturation (CVM) method for the detection of peak mandibular growth. Samples 
comprised of 30 orthodontically untreated subjects with not less than six consecutive 
cephalograms were included in the study from University of Michigan Elementary and 
Secondary school growth study. The maximum increase in Co-Gn between two consecutive 
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cephalograms was used to define peak in mandibular growth at puberty. The analysis consisted 
of both visual and cephalometric appraisals of morphological characteristics of 3 cervical 
vertebrae. The new CVM method comprises of five maturational stages with the peak in 
mandibular growth occurring between CVMS II and CVMS III . This method is particularly 
useful when skeletal maturity has to be appraised on a single cephalogram and second through 
fourth cervical vertebrae is visible even when a protective radiation collar is worn. 
Georg Brabant et al (2003) 10 analyzed the level of serum insulin like growth factor-1 using 
automated chemiluminescence immunoassay method. Totally 3961 healthy subject (2,201 Males, 
1760 Females) aged from 1 month to 88 Years were selected. Samples were collected and 
processed for the separation of serum and stored frozen at -20° or -70° C until analysis. The 
result showed a age dependency of serum IGF-1 level. At age less than 20, higher SIGF-1 level 
were seen in girl’s with an estimated peak values of 410 µg/L at age 14 and an estimated peak 
value of 382 µg/L at age 16 in boys. Thereafter, a rapid decrease was seen to approximately 25 
years of age followed by a slow age dependent decrease. 
Kouichi Itoh et al (2003) 18 studied the effects of local administration of insulin like growth 
factor-1 on mandibular condylar growth in rats. Thirty, 3 week old and 20, 12 week old male 
Sprague Dawley rats were used in the study. They were divided into control and experimental 
groups. Bacteria derived human recombinant IGF-1 was dissolved in saline to a concentration of 
20 µg/ml. The drug was injected into articular capsule on the third, fifth and seventh day. After 
administration the rats were killed and histomorphometric measurements were made from the 
prepared sections. The study concluded that local administration of IGF-1 may make it possible 
for the mandibular condyle to continue grow even after normal growth is complete. However it is 
difficult to further accelerate mandibular condyle growth during the period of growth. 
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Lily Shum et al (2004) 21 assessed the amount of vascular endothelial growth factor (VEGF) 
expression and related new bone formation in posterior glenoid fossa during stepwise mandibular 
advancement. A total of 250 female Sprague – Dawley rats, 35 day old were randomly divided 
into 2 groups, each including 5 control and 20 experimental rats. In each group, 10 experimental 
rats were fitted with functional appliances with single step advancement of 3.5mm. Another 10 
were fitted with stepwise advancement. The rats in experimental groups were killed on days 3, 7, 
14, 21, 30 , 33, 37, 44, 51 and 60 matched with their controls. Sections were cut through glenoid 
fossa sagittally and stained with anti - VEGF antibody. The results showed than an increase of 
VEGF is spatially and temporally related to amount of new bone formation in the posterior 
glenoid fossa. 
Suzuki S et al (2004) 46 studied the effects of local injection of insulin like growth factor -1 
(IGF-1) on mandibular condyle growth in mature rats . Samples consisted of sixteen, 15 week 
old male rats. In experimental group IGF-1 was injected into articular capsules of condyle at a 
concentration of 50 µg/ml, while rats in the control group were injected with equal volume of 
saline. Injections were given three times at 7 days intervals and rats were killed on 7th day after 
last injection. There was found to be significant increase in thickness of cartilaginous layer in 
IGF-1 treated condyle. The amount of endochondral bone growth was also found to be greater 
than in the control group. Thus local injection of IGF-1 seemed to reactivate the process of 
endochondral bone formation. 
H.Werner et al (2004) 54 reviewed about the role of insulin like growth factors (IGFs) in 
physiological and pathological oral processes. It had been postulated that IGF-1 affects growth 
via endocrine and paracrine/autocrine loops. In addition to its role in normal growth, the IGF is 
involved in several pathological oral processes. IGFs also regulate various aspects of salivary 
gland homeostasis. 
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Agha Hosseini et al (2005) 3 investigated the levels of vascular endothelial growth factor 
(VEGF) in unstimulated whole saliva of patients with recurrent aphthous stomatitis (RAS). 
Samples of 31 patients with RAS were selected and their saliva was collected by spitting method. 
The samples were immediately stored at -20° C until analysis. Salivary levels of VEGF were 
then determined by Sandwich ELISA using Human VEGF ELISA kit. Results were expressed in 
pg of VEGF/ml of saliva. 
Tiziano Baccetti et al (2005) 52 had done a study using cephalometric files of the University of 
Michigan Elementary and Secondary School Growth study. The total samples comprised of        
n=706 subjects. Those subjects with less than six consecutive annual cephalometric observations 
were  excluded from the study. Totally 30 subjects (18 males & 12 Females) were included. The 
maximum increase in Co-Gn between two consecutive annual cephalograms were used to define 
peak in mandibular growth at puberty. Two earlier and two later consecutive cephalograms has 
to be available for each subject. Both visual and cephalometric appraisals of morphological 
characteristics of cervical vertebrae were analyzed. The study concluded that the use of Cervical 
Vertebral Maturation method enables the clinician to identify optimal timing for the treatment of 
dentoskeletal disharmonies occurring in all three planes of space. 
Carlos Flores-Mir et al (2006) 6 assessed the correlation between Fishman maturation 
prediction method (FMP) and cervical vertebral maturation(CVM) method for determining 
skeletal maturation. Hand wrist and lateral cephalograms were taken from 79 subjects (52 
females and 27 males). Hand wrist radiographs were analyzed using FMP method and cervical 
vertebrae using CVM method for determining skeletal maturation stage. The correlation values 
was found to be moderately high between FMP and CVM. So either of the methods can be used 
indistinctively for research purposes. 
                                                                                                                           Review of literature 
  
 Page 14 
 
Paola Gandini et al (2006) 28 compared skeletal maturation using Hand Wrist bone analysis and 
cervical vertebral analysis. Radiographs of 30 patients (14 males and 16 females, 7-8 years of 
age) were examined. The hand wrist bone was evaluated by Bjork index and cervical vertebral 
analysis by cervical vertebral maturation stage (CVMS) method. The results showed correlation 
of CVMS I with Bjork stages 1&3, CVMS II with Bjork stage 4, CVMS III with Bjork stage 5, 
CVMS IV with Bjork stages 6&7 and CVMS V with Bjork stages 8&9. Thus vertebral analysis 
is as valid as hand wrist bone analysis with main advantage of reducing the radiation exposure of 
growing subjects. 
Tancan Uysal et al (2006) 49 investigated the relationship between chronologic age and skeletal 
maturation using cervical vertebrae and hand wrist radiographs. The samples consisted of lateral 
cephalometric radiographs and hand wrist radiographs of 503 subjects (213 male, 290 female, 
ages 5.3 – 24.1 years). Cervical vertebral maturation was evaluated by Hassel and Farman 
method and hand wrist radiograph by Bjork and Grave method. A high correlation coefficient 
was found between chronologic age and cervical vertebrae. Also a high correlation coefficient 
was found between hand wrist skeletal maturation and vertebral maturation. These findings 
indicate that the cervical vertebrae stages can be used as a skeletal maturity indicator of the 
pubertal growth spurt with a degree of confidence similar to other indicators.                                                                                                            
Antonelli G et al (2007) 2 evaluated the level of free IGF-1 in saliva specimen between young 
athletes and sedentary females. Saliva samples were collected from well-trained athletes and 
control group of 14 young sedentary females. Within 10-15 min of collection, samples were 
centrifuged at 2000 rpm for 10 min to remove particulate material and the clear supernatant  was 
immediately stored in vials at -80 deg C. Samples were assayed by enzyme-linked 
immunosorbent assay (ELISA) method. There was to found to be a decreased level of free IGF-1 
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in athletes when compared to sedentary females. This decrease could be related to greater tissue 
requirement by active muscles. 
Silvia Chiappin et al (2007) 39 reviewed about the saliva specimen as a new laboratory tool for 
diagnostic and various investigation purposes. The various compounds like inorganic, organic 
non protein, protein/polypeptide, hormones and lipid molecules which are present in saliva. 
Growth hormone (GH) level in human saliva was found to be 100-1000 times less than the 
physiological serum levels. Unstimulated whole saliva can be collected by a standard method 
called passive drooling method. In which saliva is allowed to drain off the lip into a sterile plastic 
vial. After the collection of saliva samples, store the samples at -20° C if the analysis is carried 
out days to months later. Thus the use of saliva samples in various assays will continue to expand 
and provides us a new tool for investigating physiologic as well as pathophysiologic status.                                                                  
Yan Gu et al (2007) 55 evaluated the mandibular dimensional changes and regional remodeling 
changes occurring during five intervals of circumpubertal growth. The samples consisted of 
longitudinal cephalometric records of 20 subjects (13 female, 7 male) included in the Mathews 
and Ware implant study. In which eleven subjects were orthodontically untreated and nine 
subjects were without treatment in mandible. Cephalograms which were available at each of six 
consecutive stages of cervical vertebral maturation were analyzed. A peak in mandibular growth 
was noted at CS3 to CS4 during puberty. Whereas mandibular remodeling and condylar rotation 
continue to occurs even after the growth spurt. 
Benny M. Soegiharto et al (2008) 5 determined and compared skeletal maturation in Indonesian 
and white children using hand wrist and cervical vertebrae maturation methods. The study 
included 2167 patients with hand wrist and lateral cephalometric radiographs. In that 648 were 
Indonesian boys, 393 white boys (age range of 10-17 years), 774 Indonesian girls and 442 white 
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girls (age range of 8-15 years). The skeletal maturation index (SMI) was used to evaluate the 
stages of skeletal maturity from hand wrist radiograph and cervical vertebrae maturation from 
lateral cephalogram. Results confirmed that variation exists between chronologic age and each 
stage of skeletal maturity between the two ethnic groups. On average the white children attained 
each stage of SMI and CVM about 0.5 to 1 year earlier than their Indonesian peers and were 
more obvious in boys. So there are differences between the timing of skeletal maturity between 
sexes and the ethnic groups.                                                                                                           
  Hessa Abdulla Alkhal et al (2008) 15 investigated the correlation between chrological age, 
cervical vertebral maturation (CVM) and Fishman’s hand wrist skeletal maturity indicators. Four 
hundred subjects with hand wrist and lateral cephalogram were randomly selected and analyzed. 
The female subjects were between 12 and 17 years of age and male subjects between 12 and 17 
years of age, all were within in the circumpubertal period. The hand wrist was assessed using the 
method developed by Fishman and CVM was assessed by the method given by Bacetti and 
coworkers. When these two methods were correlated with chronological age. The findings 
indicated that CVM is a valid indicator of skeletal growth during circumpubertal period and has 
high correlation with hand wrist maturation (HWM). However, there was found to be a low 
correlation between chronological and both CVM & HWM showing that chronological age was 
not a suitable method to identify skeletal maturity.  
Juan Dai et al (2008) 17 investigated whether the introduction of specific vascular growth 
inducting genes would favorably affect the mandibular condylar growth in Sprague – Dawley 
(SD) rats over an experimental period. Ninety 35 days old female SD rats were randomly divided 
into 3 groups. Each group received any of the injections of recombinant adeno associated virus 
mediated vascular endothelial growth factor (rAAV – VEGF), rAAV mediated enhanced green 
fluorescence protein (rAAV-eGFP) or phosphate buffered saline (PBS) into both mandibular 
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condyles. Rats of each group were sacrificed on the following experimental days of 7, 14, 21, 30 
and 60. Left halves of the mandible was isolated and digital pictures were obtained in a 
standardized manner. The length of condylar process as well as the mandibular length were 
significantly increased on 30th day and continued to increase until the end of experiment. Thus 
gene therapy with VEGF stimulates condylar growth and provides the basis to regulate 
mandibular condylar growth. 
Mohamed Masoud et al (2008) 25 assessed the skeletal maturity by using blood spot insulin like 
growth factor-1 (IGF-1). The study included 83 patients (44 female, 39 male) between age of 5 
and 25 years. Lateral cephalogram and blood sample were collected on the same day for each 
patient. The samples were assayed by radioimmunoassay and correlated with the stages of 
cervical vertebrae. The results showed that blood spot IGF-1 level is low in prepubertal CVM 
stage, then rises sharply to its peak in late puberty and decline in post puberty stages. Thus IGF-1 
level can be accurately used to determine the timing and intensity of a patient’s growth spurt.                                           
Wai Yip Lei et al (2008) 53 studied the core binding factor alfa1 (cbfa1) and vascular endothelial 
growth factor (VEGF) expressions in the spheno-occipital synchondrosis in vitro with and 
without tensile stress. Sixty one day old male BALB/c mice were randomly divided into 
experimental and control groups. Each group was subdivided into five subgroups of different 
time frames 6, 24, 48, 72 and 168 hours. Each subgroup consisted of six mice. Animals were 
sacrificed and cranical base synchondrosis were aseptically removed and mechanical stress was 
applied using helical springs and incubated as organ culture. Then the tissue sections were 
subjected to immunohistochemical staining for quantitative analysis of growth factors. 
Mechanical stress applied to spheno-occipital synchondrosis upregulates alfa1(cbfa1) and VEGF. 
So increased levels of both the factors could play a role in endochondral bone growth. 
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Antonelli et al (2009) 1 investigated the effects of physical exercise on salivary free insulin like 
growth factor-1 and plasma free IGF-1. Eighteen males at an age range of 19±1 year were 
included in the study. Saliva and blood samples were collected before and at the end of physical 
exercise. Both the saliva and blood samples were assayed by ELISA method. The results showed 
that sIGF-1 was significantly increased at the end of physical exercise whereas plasma free IGF-
1 concentrations did not demonstrate any difference.  
Mohamed I. Masoud et al (2009) 26 predicted the relationship between blood spot insulin like 
growth factor 1 levels and hand wrist assessment of skeletal maturity. Eighty four subjects (45 
female, 39 male) between the ages of 5 and 25 were included in the study. From each subjects 
hand wrist radiograph and a blood spot sample were collected on the same day. The results 
showed that IGF-1 levels were significantly higher during pubertal stage than at the prepubertal 
or postpubertal stage when compared with hand wrist maturation stages. 
Ricky W.K Wong et al (2009) 34 evaluated the validity of cervical vertebral maturation (CVM) 
method as an indicator of skeletal age in the circumpubertal period by correlating with hand 
wrist method (HWM). Hand wrist and lateral cephalometric radiographs of 400 subjects were 
randomly selected at age ranging from 10 to 15 years for girls and 12 to 17 years for boys. They 
were within the circumpubertal period. Skeletal age of each subject was assessed according to 
CVM method and HWM. All Patients in cervical vertebral stage 3 correspond to stages of   
MP3-FG or MP3-G in HWM. Thus CVM method is a valid indicator of skeletal growth during 
circumpubertal period, providing the optimum time period for growth modification procedure. 
Tahwinder Upile et al (2009) 47 had done a study to evaluate and compare the salivary VEGF 
level in healthy population and in oral cancer patients. The samples included twenty one 
participants (12 male and 9 females) of whom 14 were healthy subjects and 7 oral cancer 
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patients. Whole saliva samples were taken from each subject and assayed by chemiluminescent 
VEGF immunoassay is a 5.5 hour solid phase ELISA designed to measure VEGF level in saliva. 
The result indicated the presence of VEGF in normal healthy population is (mean = 231.609 
pg/ml) and found to be increased in the cancer patients. Thus saliva contains biologically active 
proteins, growth factors and cytokines. 
Lili Chen et al (2010) 20 investigated the relative growth rate (RGR) of maxilla and mandible 
according to quantitative cervical vertebral maturation (QCVM) of adolescents. The samples 
consisted of 87 adolescents (32 boys and 55 girls) age ranging from 8 to 18 years. Lateral 
cephalograms and hand wrist films were taken sequentially once a year for 6 consecutive years. 
The growth magnitude (GM) and relative growth rate (RGR) of maxilla and mandible were 
measured and analyzed. GM and RGR were not always consistent because each subjects had 
different periods of growth between various QCVM stages. GM was not as reliable as that of 
RGR. The greatest RGR of mandibular length and height was in QCVM stage II. So its the best 
intervention period and can be used as a reference in deciding orthodontic treatment or an 
orthognathic surgery. 
Denise Boechat Leite et al (2011) 8 analyzed insulin like growth factor-1 (IGF-1) in serum 
using an automated chemiluminescence immunoassay system. Total samples consisted of 484 
healthy subjects (251 men, 233 women) age ranging  from 18 – 70 years. The blood samples 
were collected and serum was separated and stored frozen at -20° C until analysis . The samples 
were analyzed by an automated immuno chemiluminometric assay (ICMA). The results 
demonstrated that in adulthood, a slow age dependent decrease in IGF-1 was seen and also there 
exists a significant difference between the genders. IGF-1 in women was found to be 
significantly higher than in men. 
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Gina Ball et al (2011) 11 studied the relationship between cervical vertebral maturation and 
mandibular growth. The samples consisted of 90 boys from the Burlington growth center at age 
ranging from 9 to 18 years. For determining the incremental growth of mandible the lengths were 
measured from articulare to gnathion. Cervical vertebral maturation stages were assessed by 6 
stage method. Advanced, average and delayed maturation groups were established. Minimum 
velocity of prepubertal mandibular growth occurred during cervical stage 1 and peak mandibular 
growth occurred most frequently during stage 4 in all 3 maturation groups with a statistical 
difference between each group. Progression from cervical stages 1 through 6 does not occur 
annually, time span in each stage varies depending on maturation group . This cervical vertebral 
maturation stages cannot accurate identifies the mandibular prepubertal growth. So it better to 
use with other methods when considering for dentofacial orthopedic treatment or orthognathic 
surgery. 
Mohamed I. Masoud et al (2012) 27 studied the relationship between blood spot insulin like 
growth factor ( IGF-1) and changes in mandibular growth. Twenty five patients (12 female , 13 
male) were longitudinally evaluated for annual IGF-1 level, cervical stage and mandibular 
length. Patients follow up periods ranged between 1 and 5 years. The samples were assayed by 
radioimmunoassay and the mandibular length was measured from condylion to gnathion. The 
cervical vertebrae were staged into 6 stages as described by Baccetti T. The group with 
ascending IGF-1 levels had significantly more mandibular growth than did the group with 
descending IGF-1 levels . Results suggested that blood spot IGF-1 is a promising tool for 
predicting the timing and intensity of mandibular growth spurt. 
Ramy Abdul Rahman Ishaq (2012) 33 evaluated the applicability of insulin like growth factor-1 
(IGF-1) blood level as a maturation indicator by correlating it to cervical vertebral maturation 
(CVM) method. Samples consisted of 120 subjects, equally divided into 60 males (ages 10-18 
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years) and 60 females (ages 8-16 years). Lateral cephalogram and blood samples were taken 
from each subject. Blood samples were analyzed with enzyme linked immunosorbent assay 
(ELISA) technique. The IGF-1 mean value at each cervical vertebral maturation stage was 
statistically different. Highest mean values were observed in stages 4 & 5 in males and stage 3 in 
females. Thus IGF-1 serum level is a reliable skeletal maturation indicator that could be applied 
in orthodontic diagnosis. 
Rodrigo Cesar Santiago et al (2012) 35 reviewed the reliability of cervical vertebrae maturation 
(CVM) staging to predict the pubertal growth spurt. The selection criteria for considering studies 
in this systematic review were cross-sectional or longitudinal descriptive studies that evaluated 
qualitatively or quantitatively on established CVM method on lateral cephalometric radiographs 
to determine skeletal maturation and those studies that used hand wrist radiographs as the 
standard method for comparison with the CVM method. Twenty three were finally selected and 
scored. This systematic review had shown that CVM method can be used as a radiographic 
assessment for determining skeletal maturation during orthopedic treatment. 
Yan Qi Yang et al (2012) 57 reviewed the role of vascular endothelial growth factor (VEGF) in 
ossification. Studies have shown that VEGF stimulates cell proliferation by upto 70% and 
directly promotes differentiation of primary human osteoblasts in vitro by increasing nodule 
formation and alkaline phosphatase activity in a dose dependent manner. Also reported that 
VEGF is expressed at low level in the beginning of osteoblast differentiation and its expression 
increased strongly during the period of mineralization. VEGF is able to promote ossification by 
either inducing neovascularization or by directly affecting the bone cells. 
Martin Bidlingmaier et al (2013) 23 had done a study to measure the level of IGF-1 from birth 
to senescence using a new automated chemiluminescence IGF-1 immunoassay. It is a 
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multicenter study with samples from 12 cohorts from the United States, Canada and Europe 
including 15,014 subjects (6697 males and 8317 females) age ranging from 0-94 years. The 
result of the study concluded that the IGF-1 secretion declined immediately after birth followed 
by an increase until pubertal peak (at 15 years of age) and later in life, the values decreased 
continuously. 
Sapna Jain et al (2013) 37 studied the association between serum insulin like growth factor – 1 
(IGF-1) levels with cervical maturation stages (CS) 3, 4 and 5 on lateral cephalogram. The total 
samples consisted of 45 males at skeletal maturation stage CS-3, CS-4 and CS-5. Blood samples 
were taken and serum was separated and stored at 2 to 8 degree Celsius until analysis. The 
samples were assayed by chemiluminescence immunoassay a fully automated method for 
determination of IGF-1 level. The results showed that there is a highly significant differences 
between all cervical stages. Serum IGF-1 levels showed good correlation with skeletal age in 
males 53.3% at CS-3, 66.7% at CS-4 and 6.7% at CS-5. Thus serum IGF-1 levels can be used as 
an additional diagnostic tool to optimize orthodontic treatment timing.    
Subash Nayak et al (2014) 42 had done a study to find the relationship between salivary insulin 
like growth factor-1 (IGF-1) and quantitative cervical vertebral maturational stages (QCVM) of 
skeletal maturity. The study included 24 female and 21 male between the ages of 7 and 23 years. 
QCVM staging was used to divide the subjects in to four groups. Parotid saliva samples were 
collected using Lashley cup for about 30 min and the samples were assayed by IRMA 
(Immunoradiometric assay) method. The results concluded that salivary IGF1 levels and its 
secretion rate gradually increased to a peak in the high velocity QVCM stage and decreased 
thereafter. Thus salivary IGF-1 can be used as a marker for predicting residual mandibular 
growth. 
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Yangi Yang et al (2014) 56 reviewed about the growth factors involved in mandibular condylar 
growth. It has been identified that several factors including Sox9, type II collagen, PTHrP, Ihh, 
FGFR, type X collagen, VEGF, Cbfal/Runx2 and OPG/RANKL play a pivotal role in growth 
and development of mandibular condyle. The mandibular condylar cartilage is a secondary 
cartilage influenced by both growth hormones and mechanical forces. Upon forward mandibular 
positioning by bite jumping appliance, there was found to be a significant uprelation of VEGF. 
In single step advancement VEGF expression was less when compared with stepwise 
advancement. Thus VEGF plays a vital role in regulating endochondral ossification of condyle 
by controlling neovascularization.           
Paszynska E et al (2015) 29 had done a study to measure the salivary and serum insulin like 
growth factor-1 (IGF-1) concentration of patients with anorexia nervosa (AN) in comparison to 
healthy individuals. Total samples of 121 patients and 77 individuals were selected. Blood and 
salivary samples were derived and analyzed by enzyme liked immunoassay (ELISA) suitable for 
measuring free IGF-1. There was found to be a significant reduction in free IGF-1 levels in 
saliva and serum. Thus salivary and serum IGF-1 analysis also appear to be a reliable 
biochemical indicator of malnutrition. 
Shreya Gupta et al (2015) 38 had done a cross sectional study to assess serum insulin like 
growth factor-1 (IGF-1) level at various cervical vertebral maturation (CVM) stages. The study 
included 60 subjects (30 females and 30 males) in age ranging from 8-23 years. All subjects 
serum IGF-1 levels were estimated by means of chemiluminescence immunoassay (CLIA). 
CVM was assessed on lateral cephalograms using the method given by Baccetti T. It was found 
that peak value of serum IGF-1 was observed in cervical stage CS3 in females & CS4 in males. 
The greatest mean serum IGF-1 for female is 397ng/ml which were slightly higher than in males 
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394.8 ng/ml. In this study males and females showed a slight difference in IGF-1 level at 
different cervical stages.  
Suchita M T et al (2015) 43 reviewed about the various methods which are currently used as 
skeletal maturity indicators. The timing of the growth spurt can be assessed by chronological 
age, skeletal age, physiologic age and dental age. Other methods are radiological and 
biochemical methods. In radiological method radiographs like hand wrist, lateral cephalogram 
and orthopantomogram are used.  Whereas recently biochemical methods were used for 
identification of growth factors like IGF-1, alkaline phosphosphate (ALP) and creatinine in 
saliva and serum IGF-1 is a circulating GH factor, the level of which correlates with sexual 
maturity. It is measurable in serum, urine and saliva. Various studies have shown a positive 
correlation between IGF-1 levels with cervical skeletal maturity from the prepubertal to the late 
pubertal stage. 
Sushma Dhiman et al (2015) 44 reviewed about the various methods for the assessment of 
skeletal maturity in orthodontics. These include body height, body weight, sexual maturation, 
frontal sinus, chronological age, biological age or physiological age, hand wrist radiograph, 
cervical vertebrae, dental eruption, dental calcification stages and various biomarkers. 
Biomarkers are the agents that are involved directly in both growth and remodeling. These 
biomarker avoids radiation exposure and recently many researchers are being done to explore the 
role of biomarkers for determination of skeletal maturation. 
Hechang Huang et al (2016) 14 studied the effects of vascular endothelial growth factor (VEGF) 
on osteoblasts and osteoclasts. Preosteoblastic MC3T3-E1 cells were treated with VEGF-A165. 
Also preosteoclastic RAW264.7 cells were treated with VEGF with or without the receptor 
activator of nuclear factor kappa–B ligand (RANKL). It was found that VEGF significantly 
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induced MC373-E1 osteoblast cell proliferation, migration and did not directly induce 
osteoclastogenesis but by significantly increasing the RANKL/OPG ratio from MC3Y3-E1 
cultures. 
Taye J Lasisi et al (2016) 50 investigated the effect of acute exercise on salivary flow rate and 
salivary free insulin like growth Factor-1 (IGF-1). Saliva samples were collected before and 
immediately after exercise from 22 males with a mean age of 20-46 years. The level of free  
IGF-1 in saliva was determined by enzyme like immunoassay (ELISA) kits following 
manufacturer instructions. The result concluded that the salivary flow rate is reduced and there is 
no change in the level of salivary free IGF-1. 
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MATERIALS AND METHODS 
            The study was carried out in 90 patients with no previous history of orthodontic treatment 
before with their age ranging from 6 to 20 years. The patients were selected from those who 
reported to the department for seeking orthodontic treatment. Before their entry into the study all 
the subjects were explained about the study. An informed consent form duly signed by every 
subject was obtained and ethical clearance for the study had been obtained from the Institutional 
ethical committee. 
A routine diagnostic lateral cephalogram (ORTHOPHOS XG 3D, Sirona) taken prior to 
orthodontic treatment in 90 individuals were used to assess the skeletal maturation stage. 
Grouping of samples 
           The 90 subjects were divided into 3 groups namely group I, II and III comprising of 30 
individuals in each group based upon the pubertal growth status determined by Hassel and 
Farman CVMI staging. 
Group I   – Individuals in the pre-pubertal growth stage (CS1 & CS2) 
Group II  – Individuals in the pubertal growth stage (CS3 & CS4) 
Group III – Individuals in the post pubertal stage (CS5 & CS6) 
Materials used in the study 
1) Tarsons 15 ml centrifuge tubes for collecting samples 
2) Eppendorf tubes for storage of samples 
3) Micropipette and disposable micropipette tips 
4) Laboratory centrifuge  
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5) Laboratory deep freezer 
6) IGF1 and VEGF kits 
7) 96 well micro-titer plates 
8) Microplate reader 
Inclusion criteria 
1) Age ranging from 6 to 20 years 
2) No previous history of orthodontic treatment  
3) No history of any systemic disease, hormonal imbalance and drug intake 
4) Good oral hygiene 
Exclusion criteria 
1) Craniofacial anomalies 
2) Growth retardation 
3) Any oral ulcers 
4) Xerostomia  
Determination of CVMI 
Hassel and Farman’s method of CVM index were used for determining the cervical vertebral 
maturation stages. It consists of 6 stages of skeletal maturation from CS1 to CS6. The inferior 
vertebral borders were flat when immature and they were concave when mature. The concavities 
occurs sequentially from CS2 to CS4 as skeleton matures. Also the shapes of the vertebral bodies 
change from wedge shaped, to rectangular, followed by square shape. In addition they increase 
in height as skeleton matures. 
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Stage 1 (Initiation) : Inferior borders of C2, C3 and C4 were flat and wedge shaped. The superior  
                             border tapers from posterior to anterior. 
Stage 2 (Acceleration) : Concavities were developing in the inferior borders of C2 and C3. The        
                                  inferior border of C4 was flat and vertebral bodies of C3 & C4 were  
                                  rectangular in shape. 
Stage 3 (Transition) : Distinct concavities were seen in the inferior borders of C2 and C3.  
                                 Whereas concavity is started developing in inferior border of C4.  
                                  Vertebral bodies of C3 and C4 were rectangular in shape. 
Stage 4 (Deceleration) : Distinct concavities were seen in the inferior borders of C2, C3 and C4. 
                                   Vertebral bodies of C3 and C4 were becoming squarer in shape. 
Stage 5 (Maturation) : More accentuated concavities were seen in the inferior borders of C2, C3  
                                and C4. Vertebral bodies of C3 and C4 were nearly square in shape. 
Stage 6 (Completion) :  Deep concavities were seen in the inferior borders of C2, C3 and C4. 
                                 Vertebral bodies of C3 and C4 were square and were more greater in  
                                 vertical dimension. 
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Patient preparation for saliva collection 
           Thorough oral prophylaxis was carried out before sample collection in all the participants  
who were included in the study. Mouth washes were not used by the subjects prior to sample 
collection. If so the subjects were asked to rinse with water for more than two times. Also 
subjects were asked not to drink or eat two hours prior to sample collection.          
Collection of the saliva sample 
             Unstimulated whole saliva sample was collected in this study. Saliva sample collection 
was performed according to Brozovic et al in which all the subjects were asked to retain mixed 
saliva in their mouth for 5 min without swallowing and then to expectorate into a sterile 15ml 
Tarzons centrifuge tube. Then samples were centrifuged for 10 min at 1500g at room 
temperature and stored at -20 deg C until analysis.  
Estimation of IGF-1 and VEGF 
          Before the assay thawed saliva was again centrifuged and the clear supernatant sample 
were used for the assay. Quantitative determination of IGF-1 was done by sandwich 
chemiluminescence  immunoassay. A monoclonal antibody is used for coating magnetic particles 
(solid-phase) and another monoclonal antibody is linked to an isoluminol derivative (isoluminol 
– antibody conjugate). During the incubation, IGF-1 present in calibrators, samples or controls 
binds to the solid phase as well as to the conjugate. After the incubation, the unbound material is 
removed with a wash cycle. Subsequently, the starter reagents are added and a flash 
chemiluminescence reaction is thus induced. The light signal, and hence the amount of 
isoluminol conjugate, is measured by a photomultiplier as relative light units (RLU) and is 
indicative of IGF-1 concentration present in calibrators, samples and controls. 
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          Remaining samples were used for determination of VEGF by sandwich Enzyme Linked 
Immunosorbent Assay (ELISA) method using human VEGF ELISA Kit. Add 50 µL of the 
incubation buffer to all 96 wells expect chromogen blanks. Then add 100 µL of standards to the 
appropriate microtiter wells. For samples and controls, add 50 µL of Standard Diluent Buffer to 
each appropriate well followed by 50 µL of sample or controls. Cover the plate with plate cover 
and incubate for 2 hours at room temperature. Thoroughly aspirate the solution and wash wells 4 
times with diluted Wash Buffer. Add 100 µL Hu VEGF Biotin Conjugate solution into each well 
except chromogen blanks. Cover the plate with plate cover and incubate for 1 hour at room 
temperature. Thoroughly aspirate the solution and wash wells 4 times with diluted Wash Buffer. 
Add 100 µL Streptavidin – HRP into each well except the chromogen blanks. Cover the plate 
with plate cover and incubate for 30 minutes at room temperature. Then thoroughly aspirate the 
solution from the wells and wash wells 4 times with 1X Wash Buffer. Add 100 µL Stabilized 
Chromogen to each well. The substrate solution will begin to turn blue. Cover the plate with 
plate cover and incubate for 30 minutes at room temperature in the dark. Add 100 µL Stop 
Solution to each well and tap side of the plate gently to mix. The solution in the wells changes 
from blue to yellow. 
           Read the absorbance at 450 nm within 2 hours after adding the Stop Solution. Use curve 
fitting software to generate the standard curve. Concentrations for unknown samples and control 
were read from the standard curve.
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STATISTICAL ANALYSIS 
The statistical analysis was performed with SPSS windows software (version 21, IBM USA). 
The significance level was set at P ≤ 0.05. The Kruskal – Wallis test and ANOVA was used to 
compare the mean IGF-1 and VEGF values in different cervical vertebral maturation stages. The 
Mann – Whitney U test was used to compare the mean IGF-1 and VEGF values between the 
genders in each cervical vertebral maturation stages. For multiple comparisons of samples 
among groups Post Hoc test – Bonferroni were used. 
Kruskal – Wallis test 
� = ͳʹ ͳʹ�ሺ� + ͳሻ ∑ ��ଶ − ͵ሺ� + ͳሻ��−ଵ  
Where  
H = Kruskal-Wallis Test statistic 
N = total number of observations in all samples 
Ti = Sum of the ranks assigned  
 
 ANOVA analysis  
ANOVA = BMS − WMSBMS + ሺn − ͳሻWMS 
Where 
BMS = between subjects mean sum of squares 
WMS = within subjects mean sum of squares 
n = Number of measurements 
P value of less than 0.05 was considered to be statistically significant. 
 
  Statistical Analysis 
 
 
Page 32 
 
Mann – Whitney U test 
� = �ଵ�ଶ +  �ଶ  ሺ�ଶ  + ͳሻʹ −  ∑ ���మ�=�భ+ଵ  
Where 
 
U=Mann-Whitney U test 
N1 = sample size one 
N2= Sample size two 
Ri = Rank of the sample size.
  
 
 
 
 
 
 
 
                                  RESULTS  
  Results 
 
 
Page 33 
 
RESULTS 
            The results of the study are based on the levels of insulin like growth factor (IGF-1) and 
vascular endothelial growth factor (VEGF) at various stages of cervical vertebral maturation 
(CVM).  
            Table 1 shows the total number of samples in pre-pubertal stage (CS1 and CS2) with a 
mean age of 9.3 yrs. Also it expresses the mean level of VEGF (189.73±200.63 pg/ml) and IGF-
1 (4.40±0.17 ng/ml). Table 2 shows the total number of samples in peak-pubertal stage (CS3 and 
CS4) with a mean age of 12.9 yrs. The VEGF level decreases to 97.31±141.99 pg/ml but the 
IGF-1 level was found to be increased to 6.15±1.04 ng/ml. Table 3 shows the total number of 
samples in post-pubertal stage (CS5 and CS6) with a mean age of 17.4 yrs. The level of VEGF 
decreases steadily to 58.05±87.85 pg/ml and the IGF-1 level also decreases to 4.43±0.29 ng/ml 
during this stage. 
            Table 4 shows the total number of female samples in all the 3 groups. The mean level of 
VEGF (97.25±151.65 pg/ml) and IGF-1 (4.9±1.03 ng/ml) in females were measured. Table 5 
shows the total number of male samples taken into the study with mean VEGF level of 
127.56±163.32 pg/ml and IGF-1 level of 5.11±1.05 ng/ml. 
            Table 6 shows the total number of female samples in pre-pubertal stage (CS1 & CS2) 
with a mean age of 9.1 yrs. The mean level of VEGF in female was measured to be 199.29±242 
pg/ml and IGF-1 was found to be 4.42±0.15 ng/ml. 
            Table 7 shows the total number of female samples in peak-pubertal stage (CS3 & CS4) 
with a mean age of 12.11 yrs. The measured level of VEGF in female during this stage decreases 
to 87.49±74.84 pg/ml and the IGF-1 level increases to 6.47±1.07 ng/ml. 
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            Table 8 shows the total number of female samples in post-pubertal stage (CS5 & CS6) 
with a mean age of 17 yrs. In this stage the VEGF level decreases steadily to 50.62±89.90 pg/ml 
and the IGF-1 level also decreases to 4.42±0.33 ng/ml. 
            Table 9 shows the total number of male samples in pre-pubertal stage (CS1 & CS2) with 
a mean age of 9.5 yrs. The mean VEGF level measured in males was (184.43±181.24 pg/ml) and 
the IGF-1 level was (4.39±0.18 ng/ml). 
            Table 10 shows the total number of male samples in peak-pubertal stage (CS3 & CS4) 
with a mean age of 13.2 yrs. Similarly to females the mean level of VEGF decreases to 
101.53±164.108 pg/ml and IGF-1 level increases to 6.02±1.02 ng/ml during this stage. 
            Table 11 shows the total number of male samples in post-pubertal stage (CS5 & CS6) 
with a mean age of 18.4 yrs. The mean level of VEGF decreases steadily to 74.57±85.85 pg/ml 
and IGF-1 level also decreases to 4.44±0.19 ng/ml. 
            Table 12 shows the comparison of VEGF and IGF-1 across the CVM stages. There is a 
significant difference in VEGF (P=.004) and IGF-1 level (P=.000). 
            Table 13 shows the multiple comparisons and mean difference of VEGF and IGF-1 
across the CVM stages. The data demonstrated a significant difference in VEGF level when 
group 1 and group 3 were compared (P=.004). In IGF-1 there is a highly significant difference 
when group 2 is compared with group 1 and group 3 (P=.000). 
           Table 14 shows the comparison of females across the CVM stages. There is a significant 
difference in VEGF (P=.035) and IGF-1 level(P=.000)  
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            Table 15 shows the multiple comparisons and mean difference of females across the 
CVM stages. There is a significant difference in VEGF level when group 1 and group 3 were 
compared (P=.031). In IGF-1 level also there is a highly significant difference when group 2 is 
compared with group 1 and group 3 (P=.000). 
            Table 16 shows the comparison of males across the CVM stages. There is no significant 
difference in VEGF level (P=.161) but in IGF-1 level there is a highly significant difference 
(P=.000). 
            Table 17 shows the multiple comparisons and mean difference of males across the CVM 
stages.  There is no significant difference in VEGF level was found when the three groups were 
compared. In IGF-1 level there is a highly significant difference when group 2 was compared 
with group 1 and group 3 (P=.000). 
            Table 18 shows the comparison of CVM stages across genders. There is no significant 
difference in VEGF and IGF-1 level when females and males were compared. 
            Table 19 and Graph 1 shows the mean value of IGF-1 level in both females and males 
across the CVM stages. In both the genders the IGF-1 level was found to be increased in group 2 
(F - 6.47±1.07 ng/ml, M - 6.02±0.19 ng/ml) than in group 1 (F - 4.42±0.15 ng/ml, M - 4.39±0.18 
ng/ml) and group 3 (F - 4.42±0.33 ng/ml, M - 4.44±0.19 ng/ml). 
           Table 20 and Graph 2 shows the mean value of VEGF level in both females and males 
across the CVM stages. In both the genders the VEGF level decreases steadily from group 1 (F - 
199.29±242 pg/ml, M - 184.43±181.24 pg/ml) to group 2 (F- 87.49±74.84 pg/ml, M - 
101.53±164.108 pg/ml) and group 3   (F - 50.62±89.90, M – 74.57±85.85). 
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          Table 21 and Graph 3 shows the mean value of VEGF and IGF-1 across the CVM stages 
irrespective of genders. The VEGF level decreases steadily from group 1 (189.73±200.63 pg/ml) 
to group 2 (97.3±141.99 pg/ml) and group 3 (6.15±1.04 pg/ml). whereas IGF-1 level was found 
to be greater in group 2 (6.15±1.04 ng/ml) than in group 1 (4.40±0.17 ng/ml) and group 3 
(4.43±0.29 ng/ml).  
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WORKING & RESULT TABLES 
TABLE 1: TOTAL NUMBER OF SAMPLES IN PRE PUBERTAL STAGE 
 
SAMPLE 
NO 
AGE/SEX CVMI STAGE GROUP 
VEGF 
pg/ml 
IGF-1 
ng/ml 
1 11/F Pre pubertal 1 32.568 4.41 
2 10/F Pre pubertal 1 128.965 4.25 
3 11/F Pre pubertal 1 26.631 4.39 
4 10/M Pre pubertal 1 250.798 4.14 
5 10/M Pre pubertal 1 11.278 4.19 
6 11/M Pre pubertal 1 46.035 4.44 
7 11/M Pre pubertal 1 15.594 4.48 
8 7/F Pre pubertal 1 36.533 4.67 
9 12/M Pre pubertal 1 41.413 4.6 
10 10/M Pre pubertal 1 93.718 4.69 
11 9/F Pre pubertal 1 32.769 4.36 
12 10/M Pre pubertal 1 25.798 4.46 
13 9/M Pre pubertal 1 261.766 4.53 
14 11/M Pre pubertal 1 250.301 4.43 
15 10/M Pre pubertal 1 244.165 4.24 
16 10/F Pre pubertal 1 371.423 4.39 
17 8/F Pre pubertal 1 648.55 4.49 
18 9/M Pre pubertal 1 629.675 4.54 
19 10/M Pre pubertal 1 90.484 4.2 
20 8/F Pre pubertal 1 573.799 4.32 
21 9/M Pre pubertal 1 475.73 4.63 
22 9/F Pre pubertal 1 123.7 4.69 
23 8/M Pre pubertal 1 133.349 4.28 
24 6/M Pre pubertal 1 379.047 4.17 
25 9/M Pre pubertal 1 32.595 4.43 
26 6/M Pre pubertal 1 6.709 4.56 
27 8/F Pre pubertal 1 17.971 4.27 
28 11/M Pre pubertal 1 331.348 4.11 
 
Total no: 28, Mean age: 9.3 years 
Mean±SD of VEGF = 189.73±200.63, Mean±SD of IGF-1 = 4.40±0.17 
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TABLE 2: TOTAL NUMBER OF SAMPLES IN PEAK PUBERTAL STAGE 
 
SAMPLE 
NO 
AGE/SEX CVMI STAGE GROUP 
VEGF 
pg/ml 
IGF-1 
ng/ml 
1 14/M Pubertal 2 734.42 5.14 
2 14/M Pubertal 2 21.425 5.1 
3 12/F Pubertal 2 122.413 6.34 
4 13/M Pubertal 2 7.799 4.94 
5 13/M Pubertal 2 36.112 7.12 
6 13/F Pubertal 2 188.192 5.87 
7 13/M Pubertal 2 45.226 5.32 
8 12/F Pubertal 2 194.173 7.55 
9 13/M Pubertal 2 145.641 5.78 
10 11/M Pubertal 2 30.993 7.13 
11 13/M Pubertal 2 251.571 4.89 
12 14/M Pubertal 2 101.07 7.01 
13 12/M Pubertal 2 -11.43 4.87 
14 12/M Pubertal 2 67.01 7.45 
15 14/F Pubertal 2 30.965 5.67 
16 11/F Pubertal 2 53.076 7.56 
17 13/M Pubertal 2 22.059 7.31 
18 11/F Pubertal 2 -1.833 4.78 
19 12/F Pubertal 2 -3.903 5.56 
20 15/M Pubertal 2 -17.566 5.78 
21 13/M Pubertal 2 33.833 5.45 
22 15/M Pubertal 2 223.533 7.21 
23 14/M Pubertal 2 -4.836 7.28 
24 13/M Pubertal 2 146.149 7.51 
25 13/M Pubertal 2 71.96 5.13 
26 13/M Pubertal 2 175.561 5.29 
27 14/M Pubertal 2 4.005 5.77 
28 13/M Pubertal 2 47.614 4.95 
29 11/F Pubertal 2 80.655 7.25 
30 13/F Pubertal 2 123.706 7.73 
 
Total no: 30, Mean age: 12.9 years 
Mean±SD of VEGF: 97.31±141.99, Mean±SD of IGF-1: 6.15±1.04  
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TABLE 3: TOTAL NUMBER OF SAMPLES IN POST PUBERTAL STAGE 
 
SAMPLE 
NO 
AGE/SEX CVMI STAGE GROUP 
VEGF 
pg/ml 
IGF-1 
ng/ml 
1 19/F Post pubertal 3 -23.25 4.47 
2 15/F Post pubertal 3 12.911 4.18 
3 16/F Post pubertal 3 178.87 4.23 
4 20/M Post pubertal 3 7.096 4.32 
5 17/F Post pubertal 3 -9.971 4.01 
6 15/F Post pubertal 3 336.324 5.01 
7 19/F Post pubertal 3 192.34 4.54 
8 17/F Post pubertal 3 7.443 4.34 
9 15/F Post pubertal 3 4.08 4.78 
10 20/F Post pubertal 3 -2.675 4.14 
11 16/F Post pubertal 3 48.377 4.76 
12 14/F Post pubertal 3 8.806 4.71 
13 18/M Post pubertal 3 118.368 4.61 
14 18/F Post pubertal 3 67.216 4.36 
15 18/F Post pubertal 3 -18.536 4.1 
16 15/F Post pubertal 3 104.051 5.21 
17 20/F Post pubertal 3 38.6 4.18 
18 19/M Post pubertal 3 -6.907 4.22 
19 20/M Post pubertal 3 2.138 4.31 
20 17/M Post pubertal 3 92.6 4.44 
21 16/M Post pubertal 3 67.656 4.56 
22 17/M Post pubertal 3 270.356 4.82 
23 20/M Post pubertal 3 87.143 4.51 
24 16/F Post pubertal 3 -3.479 4.75 
25 19/F Post pubertal 3 -7.799 4.34 
26 19/F Post pubertal 3 22.62 4.13 
27 15/F Post pubertal 3 22.717 4.24 
28 17/F Post pubertal 3 33.755 4.07 
29 19/M Post pubertal 3 32.703 4.23 
 
Total no: 29, Mean age: 17.4 years 
Mean±SD of VEGF: 58.05±87.85, Mean±SD: 4.43±0.29 
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TABLE 4: TOTAL NUMBER OF FEMALE SAMPLES 
 
SAMPLE 
NO 
AGE/SEX CVMI STAGE GROUP 
VEGF 
pg/ml 
IGF-1 
ng/ml 
1 11/F Pre pubertal 1 32.568 4.41 
2 10/F Pre pubertal 1 128.97 4.25 
3 11/F Pre pubertal 1 26.631 4.39 
4 7/F Pre pubertal 1 36.533 4.67 
5 9/F Pre pubertal 1 32.769 4.36 
6 10/F Pre pubertal 1 371.42 4.39 
7 8/F Pre pubertal 1 648.55 4.49 
8 8/F Pre pubertal 1 573.8 4.32 
9 9/F Pre pubertal 1 123.7 4.69 
10 8/F Pre pubertal 1 17.971 4.27 
11 12/F Pubertal 2 122.41 6.34 
12 13/F Pubertal 2 188.19 5.87 
13 12/F Pubertal 2 194.17 7.55 
14 14/F Pubertal 2 30.965 5.67 
15 11/F Pubertal 2 53.076 7.56 
16 11/F Pubertal 2 -1.833 4.78 
17 12/F Pubertal 2 -3.903 5.56 
18 11/F Pubertal 2 80.655 7.25 
19 13/F Pubertal 2 123.71 7.73 
20 19/F Post pubertal 3 -23.25 4.47 
21 15/F Post pubertal 3 12.911 4.18 
22 16/F Post pubertal 3 178.87 4.23 
23 17/F Post pubertal 3 -9.971 4.01 
24 15/F Post pubertal 3 336.32 5.01 
25 19/F Post pubertal 3 192.34 4.54 
26 17/F Post pubertal 3 7.443 4.34 
27 15/F Post pubertal 3 4.08 4.78 
28 20/F Post pubertal 3 -2.675 4.14 
29 16/F Post pubertal 3 48.377 4.76 
30 14/F Post pubertal 3 8.806 4.71 
31 18/F Post pubertal 3 67.216 4.36 
32 18/F Post pubertal 3 -18.536 4.1 
33 15/F Post pubertal 3 104.05 5.21 
34 20/F Post pubertal 3 38.6 4.18 
35 16/F Post pubertal 3 -3.479 4.75 
36 19/F Post pubertal 3 -7.799 4.34 
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37 19/F Post pubertal 3 22.62 4.13 
38 15/F Post pubertal 3 22.717 4.24 
39 17/F Post pubertal 3 33.755 4.07 
 
Total no: 39, 
Mean±SD of VEGF: 97.25±151.65,  Mean±SD of IGF-1: 4.9±1.03 
 
TABLE 5: TOTAL NUMBER OF MALE SAMPLES 
SAMPLE 
NO 
AGE/SEX CVMI STAGE GROUP 
VEGF 
pg/ml 
IGF-1 
ng/ml 
1 10/M Pre pubertal 1 250.798 4.14 
2 10/M Pre pubertal 1 11.278 4.19 
3 11/M Pre pubertal 1 46.035 4.44 
4 11/M Pre pubertal 1 15.594 4.48 
5 12/M Pre pubertal 1 41.413 4.6 
6 10/M Pre pubertal 1 93.718 4.69 
7 10/M Pre pubertal 1 25.798 4.46 
8 9/M Pre pubertal 1 261.766 4.53 
9 11/M Pre pubertal 1 250.301 4.43 
10 10/M Pre pubertal 1 244.165 4.24 
11 9/M Pre pubertal 1 629.675 4.54 
12 10/M Pre pubertal 1 90.484 4.2 
13 9/M Pre pubertal 1 475.73 4.63 
14 8/M Pre pubertal 1 133.349 4.28 
15 6/M Pre pubertal 1 379.047 4.17 
16 9/M Pre pubertal 1 32.595 4.43 
17 6/M Pre pubertal 1 6.709 4.56 
18 11/M Pre pubertal 1 331.348 4.11 
19 14/M Pubertal 2 734.42 5.14 
20 14/M Pubertal 2 21.425 5.1 
21 13/M Pubertal 2 7.799 4.94 
22 13/M Pubertal 2 36.112 7.12 
23 13/M Pubertal 2 45.226 5.32 
24 13/M Pubertal 2 145.641 5.78 
25 11/M Pubertal 2 30.993 7.13 
26 13/M Pubertal 2 251.571 4.89 
27 14/M Pubertal 2 101.07 7.01 
28 12/M Pubertal 2 -11.43 4.87 
29 12/M Pubertal 2 67.01 7.45 
30 13/M Pubertal 2 22.059 7.31 
31 15/M Pubertal 2 -17.566 5.78 
32 13/M Pubertal 2 33.833 5.45 
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33 15/M Pubertal 2 223.533 7.21 
34 14/M Pubertal 2 -4.836 7.28 
35 13/M Pubertal 2 146.149 7.51 
36 13/M Pubertal 2 71.96 5.13 
37 13/M Pubertal 2 175.561 5.29 
38 14/M Pubertal 2 4.005 5.77 
39 13/M Pubertal 2 47.614 4.95 
40 20/M Post pubertal 3 7.096 4.32 
41 18/M Post pubertal 3 118.368 4.61 
42 19/M Post pubertal 3 -6.907 4.22 
43 20/M Post pubertal 3 2.138 4.31 
44 17/M Post pubertal 3 92.6 4.44 
45 16/M Post pubertal 3 67.656 4.56 
46 17/M Post pubertal 3 270.356 4.82 
47 20/M Post pubertal 3 87.143 4.51 
48 19/M Post pubertal 3 32.703 4.23 
 
Total no: 48, 
Mean±SD of VEGF: 127.56±163.32, Mean±SD of IGF-1: 5.11±1.05 
 
TABLE 6: FEMALE SAMPLES IN PRE PUBERTAL STAGE 
SAMPLE 
NO 
AGE/SEX CVMI STAGE GROUP 
VEGF 
pg/ml 
IGF-1 
ng/ml 
1 11/F Pre pubertal 1 32.568 4.41 
2 10/F Pre pubertal 1 128.97 4.25 
3 11/F Pre pubertal 1 26.631 4.39 
4 7/F Pre pubertal 1 36.533 4.67 
5 9/F Pre pubertal 1 32.769 4.36 
6 10/F Pre pubertal 1 371.42 4.39 
7 8/F Pre pubertal 1 648.55 4.49 
8 8/F Pre pubertal 1 573.8 4.32 
9 9/F Pre pubertal 1 123.7 4.69 
10 8/F Pre pubertal 1 17.971 4.27 
  
 Total no: 10, Mean age: 9.1 years 
Mean±SD of VEGF: 199.29±242, Mean±SD of IGF-1: 4.42±0.15 
 
 
  Results 
 
 
Page 43 
 
TABLE 7: FEMALE SAMPLES IN PEAK PUBERTAL STAGE 
SAMPLE 
NO 
AGE/SEX CVMI STAGE GROUP 
VEGF 
pg/ml 
IGF-1 
ng/ml 
1 12/F Pubertal 2 122.41 6.34 
2 13/F Pubertal 2 188.19 5.87 
3 12/F Pubertal 2 194.17 7.55 
4 14/F Pubertal 2 30.965 5.67 
5 11/F Pubertal 2 53.076 7.56 
6 11/F Pubertal 2 -1.833 4.78 
7 12/F Pubertal 2 -3.903 5.56 
8 11/F Pubertal 2 80.655 7.25 
9 13/F Pubertal 2 123.71 7.73 
Total no: 9, Mean age: 12.11 years 
Mean±SD of VEGF: 87.49±74.84, Mean±SD of IGF-1: 6.47±1.07 
TABLE 8: FEMALE SAMPLES IN POST PUBERTAL STAGE 
SAMPLE 
NO 
AGE/SEX CVMI STAGE GROUP 
VEGF 
pg/ml 
IGF-1 
ng/ml 
1 19/F Post pubertal 3 -23.25 4.47 
2 15/F Post pubertal 3 12.911 4.18 
3 16/F Post pubertal 3 178.87 4.23 
4 17/F Post pubertal 3 -9.971 4.01 
5 15/F Post pubertal 3 336.32 5.01 
6 19/F Post pubertal 3 192.34 4.54 
7 17/F Post pubertal 3 7.443 4.34 
8 15/F Post pubertal 3 4.08 4.78 
9 20/F Post pubertal 3 -2.675 4.14 
10 16/F Post pubertal 3 48.377 4.76 
11 14/F Post pubertal 3 8.806 4.71 
12 18/F Post pubertal 3 67.216 4.36 
13 18/F Post pubertal 3 -18.536 4.1 
14 15/F Post pubertal 3 104.05 5.21 
15 20/F Post pubertal 3 38.6 4.18 
16 16/F Post pubertal 3 -3.479 4.75 
17 19/F Post pubertal 3 -7.799 4.34 
18 19/F Post pubertal 3 22.62 4.13 
19 15/F Post pubertal 3 22.717 4.24 
20 17/F Post pubertal 3 33.755 4.07 
Total no: 20, Mean age: 17 years 
Mean±SD of VEGF: 50.62±89.90, Mean±SD of IGF-1: 4.42±0.33 
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TABLE 9: MALE SAMPLES IN PRE PUBERTAL STAGE 
SAMPLE 
NO 
AGE/SEX CVMI STAGE GROUP 
VEGF 
pg/ml 
IGF-1 
ng/ml 
1 10/M Pre pubertal 1 250.8 4.14 
2 10/M Pre pubertal 1 11.278 4.19 
3 11/M Pre pubertal 1 46.035 4.44 
4 11/M Pre pubertal 1 15.594 4.48 
5 12/M Pre pubertal 1 41.413 4.6 
6 10/M Pre pubertal 1 93.718 4.69 
7 10/M Pre pubertal 1 25.798 4.46 
8 9/M Pre pubertal 1 261.77 4.53 
9 11/M Pre pubertal 1 250.3 4.43 
10 10/M Pre pubertal 1 244.17 4.24 
11 9/M Pre pubertal 1 629.68 4.54 
12 10/M Pre pubertal 1 90.484 4.2 
13 9/M Pre pubertal 1 475.73 4.63 
14 8/M Pre pubertal 1 133.35 4.28 
15 6/M Pre pubertal 1 379.05 4.17 
16 9/M Pre pubertal 1 32.595 4.43 
17 6/M Pre pubertal 1 6.709 4.56 
18 11/M Pre pubertal 1 331.35 4.11 
Total no: 18, Mean age: 9.5 years 
Mean±SD of VEGF: 184.43±181.24, Mean±SD of IGF-1: 4.39±0.18 
 
TABLE 10: MALE SAMPLES IN PEAK PUBERTAL STAGE 
SAMPLE 
NO 
AGE/SEX CVMI STAGE GROUP 
VEGF 
pg/ml 
IGF-1 
ng/ml 
1 14/M Pubertal 2 734.42 5.14 
2 14/M Pubertal 2 21.425 5.1 
3 13/M Pubertal 2 7.799 4.94 
4 13/M Pubertal 2 36.112 7.12 
5 13/M Pubertal 2 45.226 5.32 
6 13/M Pubertal 2 145.641 5.78 
7 11/M Pubertal 2 30.993 7.13 
8 13/M Pubertal 2 251.571 4.89 
9 14/M Pubertal 2 101.07 7.01 
10 12/M Pubertal 2 -11.43 4.87 
11 12/M Pubertal 2 67.01 7.45 
12 13/M Pubertal 2 22.059 7.31 
13 15/M Pubertal 2 -17.566 5.78 
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14 13/M Pubertal 2 33.833 5.45 
15 15/M Pubertal 2 223.533 7.21 
16 14/M Pubertal 2 -4.836 7.28 
17 13/M Pubertal 2 146.149 7.51 
18 13/M Pubertal 2 71.96 5.13 
19 13/M Pubertal 2 175.561 5.29 
20 14/M Pubertal 2 4.005 5.77 
21 13/M Pubertal 2 47.614 4.95 
Total no: 21, Mean age: 13.2 years 
Mean±SD of VEGF: 101.53±164.108, Mean±SD of IGF-1: 6.02±1.02 
 
TABLE 11: MALE SAMPLES IN POST PUBERTAL STAGE 
SAMPLE 
NO 
AGE/SEX CVMI STAGE GROUP 
VEGF 
pg/ml 
IGF-1 
ng/ml 
1 20/M Post pubertal 3 7.096 4.32 
2 18/M Post pubertal 3 118.368 4.61 
3 19/M Post pubertal 3 -6.907 4.22 
4 20/M Post pubertal 3 2.138 4.31 
5 17/M Post pubertal 3 92.6 4.44 
6 16/M Post pubertal 3 67.656 4.56 
7 17/M Post pubertal 3 270.356 4.82 
8 20/M Post pubertal 3 87.143 4.51 
9 19/M Post pubertal 3 32.703 4.23 
Total no: 9, Mean age: 18.4 years 
Mean±SD of VEGF: 74.57±85.85, Mean±SD of IGF-1: 4.44±0.19 
 
TABLE 12: COMPARISON OF VEGF AND IGF-1 ACROSS CVMI STAGES 
  
Sum of Squares df Mean Square F Sig. 
VEGPgml Between Groups 259739.121 2 129869.560 5.779 .004 
 
Within Groups 1887710.008 84 22472.738 
  
 
Total 2147449.129 86 
   IGF1ngml Between Groups 59.394 2 29.697 71.127 .000 
 
Within Groups 35.072 84 .418 
  
 
Total 94.466 86 
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TABLE 13: MULTIPLE COMPARISONS OF VEGF AND IGF1 - POST HOC TEST 
Dependent 
Variable 
(I) 
NEW 
GRP 
(J) 
NEW 
GRP Mean D (I-J) Std.Error Sig. 
95% Confidence Interval 
Lower 
Bound 
Upper 
Bound 
VEGFPgml 1 2 92.419948 39.391485 .064 -3.80823 188.64812 
  
3 131.686163* 39.718003 .004 34.66035 228.71198 
 
2 1 -92.419948 39.391485 .064 -188.64812 3.80823 
  
3 39.266215 39.038613 .952 -56.09994 134.63237 
 
3 1 -131.686163* 39.718003 .004 -228.71198 -34.66035 
  
2 -39.266215 39.038613 .952 -134.63237 56.09994 
IGF1ngml 1 2 -1.75229* .16979 .000 -2.1671 -1.3375 
  
3 -.02773 .17120 1.000 -.4459 .3905 
 
2 1 -1.75229* .16979 .000 1.3375 2.1671 
  
3 1.72455* .16827 .000 1.3135 2.1356 
 
3 1 .02773 .17120 1.000 -.3905 .4459 
  
2 -1.72455* .16827 .000 -2.1356 -1.3135 
 
TABLE 14: COMPARISON OF FEMALES ACROSS CVMI STAGES 
  
Sum of Squares df Mean Square F Sig. 
VEGPgml Between Groups 148467.246 2 74233.623 3.684 .035 
 
Within Groups 725471.800 36 20151.994 
  
 
Total 873939.046 38 
   IGF1ngml Between Groups 29.167 2 14.583 45.105 .000 
 
Within Groups 11.640 36 .323 
  
 
Total 40.807 38 
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TABLE 15: MULTIPLE COMPARISONS OF FEMALES - POST HOC TEST 
Dependent 
Variable 
 
(I) 
NEW 
GRP 
 
(J)  
NEW 
GRP 
 
Mean D (I-J) 
 
Std. Error 
 
Sig. 
 
95% Confidence Interval 
Lower 
Bound 
Upper 
Bound 
VEGFPgml 1.0 2.0 111.797122 65.225071 .285 -51.98566 275.57991 
  
3.0 148.670900* 54.979989 .031 10.61393 286.72787 
 
2.0 1.0 -111.797122 65.225071 .285 -275.57991 51.98566 
  
3.0 36.873778 56.979911 1.000 -106.20508 179.95263 
 
3.0 1.0 -148.670900* 54.979989 .031 -286.72787 -10.61393 
  
2.0 -36.873778 56.979911 1.000 -179.95263 106.20508 
IGF1ngml 1.0 2.0 -2.05489* .26126 .000 -2.7109 -13989 
  
3.0 -.00350 .22022 1.000 .5565 .5495 
 
2.0 1.0 2.05489* .26126 .000 1.3989 2.7109 
  
3.0 2.05139* .22824 .000 1.4783 2.6245 
 
3.0 1.0 .00350 .22022 1.000 -.5495 .5565 
  
2.0 -2.05139* .22824 .000 -2.6245 -1.4783 
 
TABLE 16: COMPARISON OF MALES ACROSS CVMI STAGES 
  
Sum of Squares df Mean Square F Sig. 
VEGPgml Between Groups 97719.522 2 48859.761 1.902 .161 
 
Within Groups 1156016.740 45 25689.261 
  
 
Total 1253736.263 47 
   IGF1ngml Between Groups 30.554 2 15.277 31.106 .000 
 
Within Groups 22.101 45 .491 
  
 
Total 52.655 47 
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TABLE 17: MULTIPLE COMPARISONS OF MALES - POST HOC TEST 
Dependent 
Variable 
 
(I) 
NEW 
GRP 
 
(J) 
NEW 
GRP 
 
Mean D (I-J) 
 
Std.Error 
 
Sig. 
 
95% Confidence Interval 
Lower 
Bound 
Upper 
Bound 
VEGFPgml 1.0 2.0 82.902595 51.482806 .343 -45.12384 210.9290 
  
3.0 109.860944 65.433504 .300 -52.85782 272.57971 
 
2.0 1.0 -82.902595 51.482806 .343 -210.92903 45.12384 
  
3.0 26.958349 63.856562 1.000 -131.83890 185.75560 
 
3.0 1.0 -109.860944 65.433504 .300 -272.57971 52.85782 
  
2.0 -26.958349 63.856562 1.000 -185.75560 131.83890 
IGF1ngml 1.0 2.0 -1.62492* .22511 .000 -2.1847 -1.0651 
  
3.0 -.05111 .28610 1.000 .7626 .6604 
 
2.0 1.0 1.62492* .22511 .000 1.0651 2.1847 
  
3.0 1.57381* .27921 .000 .8795 2.2681 
 
3.0 1.0 .5111 .28610 1.000 -.6604 .7626 
  
2.0 -1.57381* .27921 .000 -2.2681 -.8795 
 
TABLE 18: COMPARISON OF GENDERS ACROSS CVMI STAGES 
  
Mann-Whitney U 
Wilcoxon 
W Z 
Asymp. 
Sig 
VEGF Pre pubertal 89.000 144.000 -.048 .962 
 
Pubertal 84.000 315.000 -.475 .635 
 
Post pubertal 67.000 277.000 -1.084 .278 
IGF-1 Pre pubertal 86.500 257.500 -.168 .867 
 
Pubertal 63.000 294.000 -1.426 .154 
 
Post pubertal 76.500 286.500 -.637 .524 
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TABLE 19: MEAN IGF-1 LEVEL IN THE THREE STUDY GROUPS 
CVM Stage Group 
Mean 
Age(yrs) 
Female  Mean ± SD 
(ng/ml) 
Male  Mean ± SD 
(ng/ml) 
Pre pubertal 1 9.1 4.42 ±  0.15 4.39 ± 0.18 
Pubertal 2 12.11 6.47 ±  1.07 6.02 ± 1.02 
Post pubertal 3 17 4.42 ±  0.33 4.44 ± 0.19 
 
GRAPH 1: IGF-1 LEVEL IN BOTH THE GENDERS ACCORDING TO CVMI STAGES 
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TABLE 20 : MEAN VEGF LEVEL IN THE THREE STUDY GROUPS 
CVM Stage Group 
Mean 
Age(yrs) 
Female  Mean ± SD 
(pg/ml) 
Male  Mean ± SD 
(pg/ml) 
Pre pubertal 1 9.1 199.29 ±  242 184.43±181.24 
Pubertal 2 12.11 87.49 ±  74.84 101.53 ± 164.108 
Post pubertal 3 17 50.62  ±  89.90 74.57 ± 85.85 
 
GRAPH 2: VEGF LEVEL IN BOTH THE GENDERS ACCORDING TO CVMI STAGES 
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TABLE 21: MEAN VEGF AND IGF-1 LEVEL IN THE THREE STUDY GROUPS 
CVM Stage Group 
VEGF(pg/ml) 
Mean ± SD 
IGF-1(ng/ml) 
Mean ± SD 
Pre pubertal 1 189.73 ± 200.63 4.40 ± 0.17 
Pubertal 2 97.3 ± 141.99 6.15 ± 1.04 
Post pubertal 3 58.05 ± 87.85 4.43 ± 0.29 
 
GRAPH 3: IGF-1 LEVEL IN THREE STUDY GROUPS IRRESPECTIVE OF GENDERS 
 
 
GRAPH 4: VEGF LEVEL IN THREE STUDY GROUPS IRRESPECTIVE OF 
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DISCUSSION 
            Assessment of growth is of prime importance in the practice of orthodontics as it 
influences the diagnosis, treatment planning and eventual outcome of the orthodontic treatment. 
Decisions regarding the use of functional appliances, extraoral traction forces, extraction vs non 
extraction treatment or orthognathic surgeries are based on growth considerations. The growth 
modulation procedure carried out during the active growth period is more effective and produces 
a more successful treatment outcome. There is a wide variation between chronological age and 
skeletal age. So it is unreliable in prediction of the actual growth status.49 There are different 
methods reported by different authors to determine the skeletal maturity. The skeletal maturation 
staging by the routine lateral cephalometric radiographic method is a widely used approach to 
predict the precise timing, growth velocity and the amount of remaining growth. 
           The standard old and reliable method of evaluating skeletal growth maturation is by using 
hand wrist radiograph. The British Orthodontic Society guideline has stated that the use of 
handwrist radiograph is not indicated to predict the pubertal growth due to unwanted additional 
radiation exposure.15,20,34 Lamparski (1972) developed a method by using cervical vertebral 
maturation (CVM) index to assess the skeletal maturation. It was found to be effective and 
clinically reliable method for assessing skeletal maturity.5,11,28,35,44,51 
          Hassel and Farman (1995) developed an index for assessing the skeletal maturation based 
on the second, third and fourth cervical vertebrae even with the use of a lead collar to protect the 
thyroid which may have hindered the image of the cervical spine.11,28,35,44 Many studies had 
compared the correlation between cervical vertebrae and hand wrist bone analysis and found a 
significant correlation between both the analysis. Suggesting that either of the methods could be 
used indistinctively for research purposes. 6,15,28,34,39,4 
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              Baccetti et al 51 gave an improved version of CVM method for assessment of 
mandibular growth. The new method consists of CVMS I through CVMS V instead of Cvs 1 
through Cvs 6 in the former method and the peak in mandibular growth occurs between CVM II 
& III. Yan Gu et al 55 evaluated the mandibular dimensional changes and regional remodeling 
changes occurring during five intervals of circumpubertal growth. They found a peak increase in 
mandibular length and greatest bone apposition at condylion was seen at CS3-CS4. This is in 
accordance with the study conducted by Ball et al.11 It has been stated that the CVM method is 
valid regardless of individual variations and between various ethnic groups.11 
                 The new emerging method for determining skeletal growth is evaluation of biomarkers 
which avoids radiation exposure. Biomarkers are those agents which are directly involved in 
bone growth and remodeling. These biochemical markers of skeletal maturity were initially 
detected in serum, but now it has also been detected in saliva and its an noninvasive method.43,44 
There are many researches that are going on in this field to establish these as a new method of 
growth estimation. Recent studies evaluated the salivary IGF-1 with CVM method and found a 
significant correlation during growth period. Also presence of VEGF in normal human saliva has 
been proved by many studies.3,16,45,47,48 This study evaluates both the salivary biomarkers as a 
parameter for precise growth estimation. 
             Vascular endothelial growth factor (VEGF) was first identified as an endothelial -  
specific growth factor from bovine pituitary follicular cells by Ferrara and Davis Symth. VEGF 
is a multifunctional angiogenic cytokine involved in angiogenesis. Many studies found that 
VEGF is able to promote ossification by either inducing neovascularization or directly affecting 
the bone cells.57 Rabie et al 31 and   Lei et al 53 studied the factors regulating endochondral bone 
ossification in rats and the expression of these factors were identified by immunohistochemical 
  Discussion 
 
 
Page 54 
 
staining. The result found an increased VEGF expression by chondrocytes preceding bone 
formation. So increased level of VEGF would have a role in bone growth. Rabie et al and Shum 
et al  identified the relationship between VEGF expression and bone formation during forward 
mandibular positioning in Sprague Dawley (SD) rats. Tissue sections were made and stained 
with anti-VEGF antibodies to evaluate VEGF expression. A highest amount of VEGF expression 
was found before bone formation.21,30,32 This is in accordance with the result of  prior study. It 
was found that in vitro introduction of VEGF to cell culture stimulates osteoblast differentiation, 
proliferation and migration.14,24 
                Jaun Dai et al 17 introduced a specific vascular growth inducting genes into SD rats to 
find its effect on mandibular condylar growth. The length of the condylar process as well as the 
mandibular length were significantly increased. Thus gene therapy with VEGF have a role in 
stimulating condylar and mandibular growth.17  
             VEGF is a multifunctional cytokine and many studies had found that VEGF is 
constitutively expressed in normal human salivary glands and is secreted in the saliva of healthy 
individuals.3,16,45,47,48 For the determination VEGF whole saliva sample was taken and assayed 
either by ELISA or chemiluminescent immunoassay method. The median concentration of 
VEGF determined by ELISA method in whole saliva is (460 pg/ml) and in ductal secretions 
obtained from the parotid is (277 pg/ml) and submandibular & sublingual salivary gland is (80 
pg/ml). VEGF seems to be synthesized endogenously by salivary glands because both VEGF 
mRNA and protein are revealed in reverse transcriptase-PCR and by immunohistochemistry.48 
             None of the studies in literature correlated the levels of salivary VEGF with various 
stages of cervical vertebral maturation for predicting the skeletal growth. In our study the mean 
salivary VEGF level in group 1 was found to be (189.73±200.63 pg/ml) and it decreases in group 
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2 (97.3±141.99 pg/ml) & group 3 (58.05±87.85 pg/ml). When multiple comparisons were made 
across CVM stages there is a highly statistically significant difference between group 1 and 
group 3 (P=.004). When females were compared there is a significant difference between group 
1 and group 3 (P=.031) and in males there is no significant difference. Also there is no 
significant difference in VEGF level when genders are compared. The mean VEGF level 
decreases from pre pubertal to post pubertal stages. This decrease in salivary VEGF level may be 
due to decreased need of tissue angiogenesis. 
            Insulin like growth factor-1 (IGF-1) was initially identified as liver derived “sulfaction 
factors” that mediates the effects of growth hormone by Salmon and Daughaday.54 IGF-1 is a 
circulating GH factor, the level of which correlates with the sexual maturity.43 Masoud et al 
evaluated the blood spot IGF-1 level with hand wrist radiographic analysis and cervical vertebral 
analysis. The results showed a significant raise in IGF-1 level during peak pubertal growth stage 
than at pre pubertal or post pubertal growth stages. So the blood spot IGF-1 can be taken as a 
promising tool for predicting the timing and intensity of mandibular growth spurt.25,26,27  
                 Gupta et al 38 and Jain et al 37 correlated the serum IGF-1 level with various stages of 
CVM and found that there is a significant increase in IGF-1 level during peak pubertal growth 
period. Between males and females also there was a significant difference. The greatest mean 
serum IGF-1 level in female is 397 ng/ml which were slightly higher than in males 394.8 
ng/ml.38 Similarly Brabant et al 10 and Leite et al 8 determined the IGF-1 factor using 
chemiluminescence immunoassay and found a age dependency of IGF-1 level. In female IGF-1 
level was found to be significantly greater than in men. This is in accordance with the study 
conducted by Gupta et al.38  
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            Local administration of IGF-1 into articular capsule of rats at different time intervals 
produced a significant increase in thickness of condyle at cartilaginous layer. The amount of 
endochondral bone growth was also found to be greater in IGF-1 treated group. Local 
administration of IGF-1 makes it possible to extend the growth of mandibular condyle even after 
normal growth is complete but its difficult to further accelerate the mandibular growth in its 
growth period.18,46    
             The determination of IGF-1 in blood is an invasive method and many studies had been 
done in the saliva to evaluate the level of IGF-1. The whole saliva samples were taken for the 
assay.1,2,7,13,29,36 Antonelli et al 1,2 evaluated the level of salivary IGF-1 in young athletes and 
sedentary females. There was a decreased level of free IGF-1 in athelets when compared to 
sedentary females and this decrease could be attributed to greater tissue requirements. Halimi et 
al 13 and Costigan et al 7 compared the salivary IGF-1 and serum IGF-1 in acromegalic patients 
to evaluate the disease activity. There was a significant increase in serum IGF-1 level than 
salivary IGF-1 which reflects the growth hormone status of an individual. The salivary IGF-1 
level was found to be less when compared to serum IGF-1. Ryan et al 36 found a significant raise 
in salivary IGF-1 level during puberty and then decreases in late adolescence. Salivary IGF-1 
concentrations were 100 to 200 folds less than the plasma IGF-1 level. Nayak et al 42 studied the 
relationship between salivary IGF-1 level and CVM stages. There was a significant correlation 
between salivary IGF-1 and CVM stages suggesting that it can be used as a biochemical marker 
for predicting growth. 
            In our study whole saliva sample was taken for the determination of IGF-1 level and 
compared with the CVM stages. There is a highly statistically significant difference between 
peak pubertal growth stage and the other two stages (P=.000). IGF-1 level was found to be at 
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baseline during pre-pubertal stage (4.40±0.17 ng/ml), then increases to its maximum level at 
peak pubertal growth  (6.15±1.04 ng/ml) and decreases again in post pubertal stage (4.43±0.29 
ng/ml).  
            When females and males were compared separately across the CVM stages the result 
showed a significant difference when group 2 is compared with group 1 and group 3 (P=.000). 
The result is in accordance with the study conducted by Nayak et al 42 and Ryan et al.36 If 
females and males were compared across the CVM stages there is no significant difference 
between genders. This was also in accordance with the study conducted by Ryan et al. 36  
              As VEGF level is highly variable it cannot be used as a biomarker for studying growth. 
But salivary IGF-1 level correlates well with the CVM stages. So IGF-1 is a valid indicator for 
predicting growth status of an individual with the advantage of avoiding the radiation exposure, 
misleading nature of the two dimensional radiograph and also it’s a non-invasive method. 
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SUMMARY 
The present study was undertaken 
1. To find out the level of salivary insulin like growth factor - 1 during the various stages of 
cervical vertebral maturation. 
2. To find out the level of vascular endothelial growth factor during the various stages of 
cervical vertebral maturation. 
3. To find out whether there is any gender differences in vascular endothelial growth factor 
level and insulin like growth factor - 1 level. 
4. To find out whether the salivary insulin like growth factor - 1 and vascular endothelial 
growth factor can be used as a biomarker to determine the overall skeletal maturity of an 
individual by correlating its value with the CVMI stages. 
The study shows a significant increase in insulin like growth factor - 1 during peak pubertal 
growth when compared with the cervical vertebral maturation method. Vascular endothelial 
growth factor level was found to be highly variable between the three study groups. When 
females and males were compared there is no significant difference in both of these 
biomarkers. The mean salivary IGF-1 level found in our study during the three growth stages 
are pre pubertal = 4.40±0.17 ng/ml, peak pubertal = 6.15±1.04 ng/ml and at post pubertal = 
4.43±0.29 ng/ml. The statistical difference between the study groups could only be 
established for VEGF level and no normal or standard VEGF values could be established for 
the three groups which requires a longitudinal study with great deal of scientific basis and a 
large sample size.  
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CONCLUSION 
There is a significant increase in salivary insulin like growth factor - 1 level during the peak 
pubertal growth when compared with pre-pubertal and post-pubertal growth stages. 
This increased salivary insulin like growth factor - 1 level correlates with the cervical vertebral 
radiograph. 
The salivary vascular endothelial growth factor level is highly variable among the three groups. 
There is no significant difference in salivary insulin like growth - 1 level and salivary vascular 
endothelial growth factor level between the genders. 
The mean salivary IGF-1 level found in our study during the three growth stages are pre pubertal 
= 4.40±0.17 ng/ml, peak pubertal = 6.15±1.04 ng/ml and at post pubertal = 4.43±0.29 ng/ml. 
No normal and standard values for salivary vascular endothelial growth factor could be 
established for each cervical vertebral maturation stages because of the varying velocity of 
growth between the individuals. 
Hence salivary insulin like growth factor - 1 level can be used  to predict the growth status of a 
healthy individual. 
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                             ANNEXURE  
KSR INSTITUTE OF DENTAL SCIENCE AND RESEARCH 
DEPARTMENT OF ORTHODONTICS AND DENTOFACIAL ORTHOPEDICS 
INFORMED CONSENT FORM 
  For questions about the study contact: 
  PRINCIPAL INVESTIGATOR :   Dr.S.SHARMILAA, 
                                                              Post graduate student, 
                                                                  Department of Orthodontics and Dentofacial Orthopaedics, 
                                                              KSR Institute of Dental Science and Research, 
                                                              Tiruchengode. 
                                                              Contact no :  9442493644 
   DESCRIPTION : 
                     You are invited to participate in the research conducted in the Department of 
Orthodontics and Dentofacial Orthopaedics, KSR Institute of Dental Science and Research.  
                     The study is to evaluate the IGF-1 and VEGF levels in saliva and its relation with the 
CVMI stages in determining the skeletal maturity 
RISK AND BENEFITS : 
                     We do not expect any adverse effects to the subject during this study.  
TIME INVOLVEMENT : 
                     Your participation time in this study will involve approximately 30 minutes during the 
procedure. 
We kindly inform you that you will not receive any financial benefits from this study. Your 
decision whether or not to participate in this study will not affect your employment/medical 
care. 
 
PARTICIPANTS’ RIGHTS : 
                 If you have read this form and have decided to participate in this project, please 
understand your participation is voluntary and you have the right to withdraw your consent 
or discontinue participation at any time without penalty or loss of benefits to which you are 
otherwise entitled.  
                       If you agree, your identity will be made known in all written data resulting 
from the study. Otherwise, your individual privacy will be maintained in all published and 
written data resulting from the study. 
An extra signed copy of this consent form will be provided to you. 
  
CONSENT : 
                       I Mr/Ms/Mrs.____________________________, read the consent form completely 
and have explained about the study well to my knowledge and also about the risks and benefits 
involved in the study by the principle investigator. I, without any compulsion, voluntarily is willing 
to participate in this study. 
  
Signature of the participant   :  ________________________ 
Signature of the investigator  :  ________________________ 
Date                                     :  ________________________ 
KSR gy; kUj;Jtf; fy;Y}hp kw;Wk; Muha;r;rp  ikak; 
xg;Gjy; gbtk; 
tpsf;fk; 
 vq;fs; gy; rPuikg;Gj; Jiwapy; eilngWk; ,e;j Muha;r;rpapy; fye;J nfhs;s 
cq;fis miof;fpNwhk;. 
 ,e;j Muha;r;rp> ckpo; ePiuf; nfhz;L> cq;fspd; tsh;r;rpiaf; 
fzf;fpLtjw;fhf mikf;fg;gl;ljhFk;. 
 ,e;j Muha;r;rpapd; NghJ> gq;Nfw;gthpd; tha; KOjhf Rj;jk; nra;ag;gLk;. 
gpd;dh; ckpo;ePh; Nrfhpf;fg;gLk;. 
gf;f tpisTfs; kw;Wk; ed;ikfs; 
 ,e;j Muha;r;rpapd; NghJ ve;j xU gf;f tpisTk; Vw;glhJ. 
 ,e;j Muha;r;rpapy; gq;Nfw;gjd; %yk;> gq;Nfw;gthpd; tsh;r;rp epiyAk; kw;Wk; 
mtuJ tsh;r;rp epiyapy; rhj;jpakhd rpfpr;ir KiwfSk; tpsf;fg;gLk;. 
 ,e;j Muha;r;rpapy; gq;Nfw;f> gq;Nfw;gth; kUj;Jtkidapy; Vwj;jho 30 
epkplq;fs; ,Uf;f Ntz;Lk;. 
 ,e;j Muha;r;rpapy; gq;Nfw;gjd; %yk;> jq;fSf;F ve;j xU epjp cjtpAk; 
toq;fg;gl khl;lhJ. 
 ,e;j Muha;r;rpapy; gq;Nfw;gJk;> gq;Nfw;fhjJk;> jq;fspd; kUj;Jt rpfpr;iria 
ve;j tpjj;jpYk; ghjpf;fhJ. 
gq ;Nfw;gthpd; chpikfs; 
 ,e;jg; gbtj;ijg; gbj;j gpd;G> jq;fSf;F ,e;j Muha;r;rpapy; gq;Nfw;f tpUg;gk; 
,Ue;jhy;> mJ cq;fspd; KO tpUg;gNk jtpu fl;lhak; ,y;iy vd;gij czu 
Ntz;Lk;. 
 jq;fspd; rk;kjj;jpd; Nghpy;> jq;fspd; milahsk; ,e;j Muha;r;rpapd; Kbtpy; 
ntspaplg;gLk;. ,y;iynadpy;> ,e;j Muha;r;rpapd; KbT ntspaplg;gLk; NghJ> 
jq;fspd; milahsk; ntspaplg;glkhl;lhJ. 
 ,e;jg; gbtj;jpd; efy; cq;fSf;F toq;fg;gLk; 
 
 
 
xg;Gjy; 
 jpU / jpUkjp ............................................................................. Mfpa ehd;> Nkw;fz;l 
xg;Gjy; gbtj;ij njspthfg; gbj;Jk;> kUj;Jthpd; KO tpsf;fq;fis Nfl;Lk;> ,e;j 
Muha;r;rpapd; KO tptuq;fis mwpe;J nfhz;L ahUila J}z;LjYk;> fl;lhaKk; 
,d;wp vd; kfd; / kfis ,e;j Muha;r;rpapy; gq;Nfw;f KO kdJld; rk;kjpf;fpNwd;. 
 
..............................................................    ....................................  
ngw;Nwhh; / ghJfhtyh; ifnahg;gk ;      Njjp 
 
 
..............................................................    .................................... 
xg;Gjy; thq;Fgthpd; ifnahg;gk;               Njjp 
 
..............................................................    .................................... 
rhl;rpf; ifnahg;gk ;                Njjp 
S.NO PATIENTS NAME AGE SEX OP.NO CVMI 
STAGE 
GROUP 
1. N.Nagalakshmi 11 F 432328 Stage 2 1 
2. G.Haswanth 14 M 322213 Stage 3 2 
3. M.Dhanujasree 10 F 10534C Stage 2 1 
4. R.Tamil Selvi 19 F 433536 Stage 6 3 
5. S.Sureka 15 F 355034 Stage 5 3 
6. M.Ajay Kumar 14 M 436015 Stage 4 2 
7. B.Divya Lakshmi 16 F 384101 Stage 5 3 
8. A.Srinath 20 M 11903C Stage 6 3 
9. R.Deepika 12 F 431434 Stage 3 2 
10. M.Mumtaj Begam 17 F 437808 Stage 5 3 
11. A.Kiruthiga 11 F 454702 Stage 2 1 
12. R.Naveen 13 M 450692 Stage 4 2 
13. A.Kavin 13 M 432035 Stage 3 2 
14. R.Abirami 15 F 439888 Stage 5 3 
15. S.Sanmuga Priya 13 F 432043 Stage 4 2 
16. R.Sujan 13 M 430793 Stage 3 2 
17. B.Madhumalathi 12 F 437805 Stage 3 2 
18. V.Kabiyashwanth 13 M 435992 Stage 3 2 
19. M.Rama Prabha 19 F 416872 Stage 6 3 
20. A.Naren Karthick 11 M 434464 Stage 3 2 
21. S.Gokuladharani 17 F 435988 Stage 6 3 
22. S.Chandru 9 M 251071 Stage 2 1 
23. P.Tharun 10 M 447220 Stage 2 1 
24. S.Asvitha 15 F 274179 Stage 5 3 
25. A.Makilesh 13 M 351649 Stage 3 2 
26. A.Guhan Karthik 10 M 434465 Stage 2 1 
27. S.Monish 11 M 353048 Stage 2 1 
28. R.Ramya 20 F 353376 Stage 5 3 
29. R.Aravindhan 11 M 402628 Stage 2 1 
30. S.Preethi 16 F 376667 Stage 5 3 
31. B.Dineshwaran 14 M 353344 Stage 4 2 
32. V.Dhanusri 7 F 369532 Stage 2 1 
33. J.Nithya Shree 14 F 432654 Stage 5 3 
34. N.Sabareeswaran 12 M 314970 Stage 2 1 
35. S.Swamidharanidharan 10 M 351125 Stage 2 1 
36. K.Dharneesh 12 M 285128 Stage 3 2 
37. R.Lokeshwaran 12 M 362721 Stage 3 2 
38. S.Harini 9 F 10463C Stage 2 1 
39. S.Gokula Kannan 18 M 431413 Stage 6 3 
40. R.Aarthi 18 F 448156 Stage 5 3 
41. M.Devi Priyadharshini 18 F 463539 Stage 5 3 
42. S.Perarasu 10 M 267537 Stage 2 1 
43. M.Surya 9 M 353372 Stage 2 1 
44. K.Manoj Kumar 11 M 427146 Stage 2 1 
45. R.Shivani Sree 15 F 437478 Stage 5 3 
46. J.Gopika 14 F 440176 Stage 4 2 
47. P.Roobalakshmi 11 F 456250 Stage 3 2 
48. S.Thiyaneshwaran 10 M 343491 Stage 2 1 
49. C.Thamizhazhagan 13 M 436284 Stage 3 2 
50. S.Vasundhara Devi 10 F 12663C Stage 2 1 
51. S.Bavika 8 F 344926 Stage 2 1 
52. G.Priyanka 20 F 359917 Stage 5 3 
53. S.Siva Ranjani 11 F 452881 Stage 3 2 
54. S.Vidhya Sri 12 F 462347 Stage 3 2 
55. T.Sathish 10 M 417471 Stage 2 1 
56. R.Shashagan 19 M 435676 Stage 6 3 
57. R.Jashwanth 10 M 436887 Stage 2 1 
58. V.Prakash 20 M 448424 Stage 6 3 
59. A.Manoj 17 M 436581 Stage 5 3 
60. M.Mukilan 16 M 434171 Stage 5 3 
61. G.Praveen 15 M 439902 Stage 4 2 
62. R.Vishnu Priya 8 F 379792 Stage 2 1 
63. S.Yogeshwaran 9 M 364455 Stage 2 1 
64. N.Subashree 9 F 337399 Stage 2 1 
65. K.Nandha Kumar 17 M 433232 Stage 5 3 
66. A.Saravana Surya 20 M 411908 Stage 6 3 
67. S.Mahanandhin 13 M 353892 Stage 4 2 
68. M.Dhevadharshini 16 F 440483 Stage 5 3 
69. S.Tuhin 8 M 386118 Stage 2 1 
70. B.Bharathi 19 F 442557 Stage 6 3 
71. J.Faijur Rahman 15 M 411930 Stage 4 2 
72. S.Pranesh 6 M 402300 Stage 2 1 
73. S.Aparna 19 F 423542 Stage 5 3 
74. S.T.Ragunath 9 M 426837 Stage 2 1 
75. R.Dharshan 6 M 339415 Stage 2 1 
76. S.Srinidhi 8 F 451138 Stage 2 1 
77. A.S.Kiruthik 14 M 402628 Stage 4 2 
78. S.Bhuvaneshwari 15 F 428662 Stage 5 3 
79. S.Kavin 13 M 431419 Stage 3 2 
80. S.Hariprasath 13 M 432332 Stage 3 2 
81. T.Nadhiya 17 F 426244 Stage 5 3 
82. S.Mohanraj 12 M 448755 Stage 2 1 
83. K.Sownther 13 M 347745 Stage 3 2 
84. K.Sridhar 11 M 10537/C Stage 2 1 
85. V.Yukesh 14 M 445548 Stage 4 2 
86. P.Sabari 13 M 246646 Stage 3 2 
87. A.Harshini 11 F 432027 Stage 3 2 
88. J.Appas 19 M 432360 Stage 6 3 
89. R.Janani Priya 13 F 431800 Stage 3 2 
90. S.Arsath 17 M 432949 Stage 5 3 
 

